

# HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2020 OF THE CONDITION AND AFFAIRS OF THE

# Arcadian Health Plan, Inc.

NAIC G	·		ode <u>12151</u> Employer's l	ID Number20-10	01348
Organized under the Laws of	(Current) (Pr Washing	ior) gton	, State of Domicile or Port of E	ntry	WA
Country of Domicile		United State	es of America		
Licensed as business type:		Health Maintena	nce Organization		
Is HMO Federally Qualified? Ye	es[X]No[]				
Incorporated/Organized	04/06/2004		Commenced Business		01/01/2005
Statutory Home Office	300 Deschutes Way SV	V, Suite 304	3	Tumwater, WA, US 98	3501
	(Street and Num	nber)	(City o	or Town, State, Country a	nd Zip Code)
Main Administrative Office			Main Street d Number)		
	Louisville, KY, US 40202	,	,,	502-580-1000	
	own, State, Country and Zip Co	de)		Area Code) (Telephone M	
Mail Address	P.O. Box 740036 (Street and Number or P.O	. Box)		Louisville, KY, US 4020 or Town, State, Country a	
Primary Location of Books and F	Records	500 West	Main Street		
	Louisville, KY, US 40202	(Street an	d Number)	502-580-1000	
	own, State, Country and Zip Co	de)	·(/	Area Code) (Telephone N	Number)
Internet Website Address		www.hur	nana.com		
Statutory Statement Contact				502-580-16	
DC	۲) IINQUIRIES@humana.com	lame)	,	(Area Code) (Teleph 502-580-2099	one Number)
	(E-mail Address)			(FAX Number)	
President	Bruce Dale Bro		CERS Chief Financial Officer	Elizab	eth Lisa Ferrari #
Associate VP, Asst Gen		035810		Liizabe	
Counsel & Corporate Secretary	Joseph Matthew	Ruschell	SVP, Chief Actuary	Vanes	sa Marie Olson
			HER		
Alan James Bailey, Courtney Danielle Durall, Ass	istant Corporate Secretary	Jeffrey Carl Fernandez,	, Chief Executive Officer SVP, Medicare West and		esendorf III, Appointed Actuary nter, Segment President, Group &
and Legal Brian Andrew Kane, Ex	ecutive VP, Finance		etPOINT Culley, SVP, Medicare		litary Business Moore #, Regional President
Sean Joseph O'Reilly, SVP, Chief Complia	nce Officer	William Mark Pres	ton, VP, Investments	Richard Donald Remr	ners, SVP, Employer Group Sales
George Renaudin II, SVP, M Gilbert Alan Stewart, SVP, M			bbinson, SVP, Tax , Medicare Divisional Leader	Susan Draney Sc	hick #, SVP, Employer Group
<u> </u>			OR TRUSTEES		
Ricky Howa	d Beavin		le Broussard	Bria	n Andrew Kane
State of	Kentucky				
County of	Jefferson	— SS: —			
The officers of this reporting ont	ty being duly sworn, each depo	so and say that they are th	he described officers of said rea	porting optity, and that or	n the reporting period stated above
all of the herein described asse	ts were the absolute property	of the said reporting entity	y, free and clear from any lien	ns or claims thereon, exc	cept as herein stated, and that this the assets and liabilities and of the
condition and affairs of the said	reporting entity as of the reporti	ng period stated above, a	nd of its income and deduction	is therefrom for the period	d ended, and have been completed ate law may differ; or, (2) that state
rules or regulations require dif	ferences in reporting not rela	ted to accounting practic	es and procedures, according	g to the best of their in	nformation, knowledge and belief he NAIC, when required, that is ar
					is regulators in lieu of or in addition
Bue Bro	marl	$C \uparrow$	m-p	ala	J. Bailey
Bruce Dale Brous		Joseph Matt	hew Ruschell		Alan James Bailey
President			ral Counsel & Corporate retary		VP & Treasurer
			a. Is this an original filir	ng?	Yes [X] No []
Subscribed and sworn to before 22nd day of	me this February	/. 2021	<ul><li>b. If no,</li><li>1. State the amendm</li></ul>		
Julia Wenter			2. Date filed		
Nia Wentworth Notary Public	<i>W.</i>		3. Number of pages	ลแสบายน	
January 10, 2025	Julia Wentworth Notary Public				
STATUS AUGULIC	State at Large				
The CARSE S	Kentucky				

ASSEIS										
	-	1	Current Year 2	3	Prior Year					
		I	2	Net Admitted Assets	Net Admitted					
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets					
1.	Bonds (Schedule D)		0							
2.	Stocks (Schedule D):									
	2.1 Preferred stocks	0	0	0	0					
	2.2 Common stocks		0	0	0					
			0							
	Mortgage loans on real estate (Schedule B):									
	3.1 First liens									
	3.2 Other than first liens	0	0	0	0					
4.	Real estate (Schedule A):									
	4.1 Properties occupied by the company (less \$0									
	encumbrances)	0	0	0	0					
	4.2 Properties held for the production of income (less									
	\$0 encumbrances)	0	0	0	0					
		0	0	0	0					
	4.3 Properties held for sale (less \$0									
	encumbrances)	0	0	0	0					
5.	Cash (\$154,421,484 , Schedule E - Part 1), cash equivalents									
	(\$									
	investments (\$23,498,442 , Schedule DA)	353 106 165	0	353 106 165	272 097 911					
6	Contract loans, (including \$			0						
	Derivatives (Schedule DB)			0	0					
	Other invested assets (Schedule BA)			0	0					
	Receivables for securities				0					
10.	Securities lending reinvested collateral assets (Schedule DL)	0	0	0	0					
	Aggregate write-ins for invested assets			0	0					
	Subtotals, cash and invested assets (Lines 1 to 11)				1.086.006.562					
	Title plants less \$0 charged off (for Title insurers									
		0	0	0	0					
	only)									
14.	Investment income due and accrued	5,210,446	0	5,210,446	4,411,674					
	Premiums and considerations:									
	15.1 Uncollected premiums and agents' balances in the course of collection		1,596,121							
	15.2 Deferred premiums and agents' balances and installments booked but									
	deferred and not yet due (including \$0									
	earned but unbilled premiums)	0	0	0	0					
		0	0	0	0					
	15.3 Accrued retrospective premiums (\$									
	contracts subject to redetermination (\$94,984,475 )		0							
16.	Reinsurance:									
	16.1 Amounts recoverable from reinsurers	0	0	0	0					
	16.2 Funds held by or deposited with reinsured companies	0	0	0	0					
	16.3 Other amounts receivable under reinsurance contracts			0	0					
	Amounts receivable relating to uninsured plans									
	Current federal and foreign income tax recoverable and interest thereon									
	Net deferred tax asset									
	Guaranty funds receivable or on deposit			0						
20.	Electronic data processing equipment and software	0	0	0	0					
21.	Furniture and equipment, including health care delivery assets									
	(\$0 )	0	0	0	0					
22.	Net adjustment in assets and liabilities due to foreign exchange rates				0					
	Receivables from parent, subsidiaries and affiliates				0					
	Health care (\$									
	Aggregate write-ins for other than invested assets			0	0					
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	1 600 750 500	24 070 000	1,596,487,759	1 0/6 050 700					
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	٥	n	0	n					
20			34,270,823	1,596,487,759	1 2/6 050 700					
	Total (Lines 26 and 27)	1,630,758,583	34,210,823	1,090,407,709	1,246,852,729					
	DETAILS OF WRITE-INS									
1101.		0	0	0	0					
1102.										
1103.										
	Summary of remaining write-ins for Line 11 from overflow page			n	n					
		0		0	······0					
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)		-		0					
	Prepaid Commissions		10,710,045	0	0					
2502.	Provider Contracts		6,827,832	0	0					
2503.	Prepaid Expenses			0	0					
	Summary of remaining write-ins for Line 25 from overflow page		0	0	0					
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	22,203,537	22,203,537	0	0					
∠ບອອ.	1 Julio (Lines 2001 linu 2000 pius 2000)(Line 20 abuve)	22,200,001	22,200,007	0	0					

# ASSETS

# LIABILITIES, CAPITAL AND SURPLUS

	-	1	Current Year 2	3	Prior Year 4
			-		·
		Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$0 reinsurance ceded) Accrued medical incentive pool and bonus amounts				
2. 3.	Unpaid claims adjustment expenses.				
3. 4.	Aggregate health policy reserves, including the liability of				2,240,000
4.	\$0 for medical loss ratio rebate per the Public				
	Health Service Act	12 027 117	0	12 027 117	15 257 099
5.	Aggregate life policy reserves.				
6.	Property/casualty unearned premium reserves.				0
7.	Aggregate health claim reserves.				0
8.	Premiums received in advance.				
9.	General expenses due or accrued				
10.1					
	(including \$1,457,957 on realized capital gains (losses))	5.476.067	0	5.476.067	4.838.358
10.2	Net deferred tax liability				0
11.	Ceded reinsurance premiums payable				0
12.	Amounts withheld or retained for the account of others.	378			
13.	Remittances and items not allocated.	1.085.310			1,072,548
14.	Borrowed money (including \$0 current) and	, .,.			····· , , , , , , , , , , , , , , , , ,
	interest thereon \$0 (including				
	\$0 current)	0	0	0	0
15.	Amounts due to parent, subsidiaries and affiliates			15.412.094	
16.	Derivatives				
17.	Payable for securities				
18.	Payable for securities lending				0
19.	Funds held under reinsurance treaties (with \$0				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$	0		0	0
20.	Reinsurance in unauthorized and certified (\$0 )				
	companies	0		0	0
21.	Net adjustments in assets and liabilities due to foreign exchange rates			0	
22.	Liability for amounts held under uninsured plans		0		
23.	Aggregate write-ins for other liabilities (including \$				
	current)		0		
24.	Total liabilities (Lines 1 to 23)				
25.	Aggregate write-ins for special surplus funds			0	
26.	Common capital stock				
27.	Preferred capital stock		XXX	0	0
28.	Gross paid in and contributed surplus				
29.	Surplus notes			0	0
30.	Aggregate write-ins for other than special surplus funds	XXX	xxx	0	0
31.	Unassigned funds (surplus)	XXX	XXX		
32.	Less treasury stock, at cost:				
	32.10 shares common (value included in Line 26				
	\$0 )	XXX	XXX	0	0
	32.20 shares preferred (value included in Line 27				
	\$0 )	XXX	XXX	0	0
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)	XXX	XXX		716,768,438
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	1,596,487,759	1,246,852,729
	DETAILS OF WRITE-INS				
2301.	Unclaimed Property		0		
2302.					
2303.					
2398.	Summary of remaining write-ins for Line 23 from overflow page	0	0	0	0
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	391,795	0	391,795	75,190
2501.	Special Surplus - Projected HCRL Assessment for the Upcoming Year	xxx		0	
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page			0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	0	86,545,504
3001.				0	0
3002.					
3003.					
3098.	Summary of remaining write-ins for Line 30 from overflow page			0	0
	Totals (Lines 3001 thru 3003 plus 3098)(Line 30 above)	XXX	XXX	0	0

# STATEMENT OF REVENUE AND EXPENSES

	STATEMENT OF REVENUE AN	Current		Prior Year
		1 Uncovered	2 Total	3 Total
1. N	Nember Months		1	
2. N	et premium income ( including \$	XXX	5,513,801,635	4,345,827,532
3. C	hange in unearned premium reserves and reserve for rate credits	XXX	0	0
4. F	ee-for-service (net of \$0 medical expenses)	XXX	0	0
5. R	isk revenue	XXX	0	0
6. A	ggregate write-ins for other health care related revenues	XXX	0	0
7. A	ggregate write-ins for other non-health revenues	XXX	0	0
8. T	otal revenues (Lines 2 to 7)	XXX	5,513,801,635	4,345,827,532
	ospital and Medical:			
	ospital/medical benefits			
	ther professional services			
	utside referrals			
	mergency room and out-of-area			
	rescription drugs			
	ggregate write-ins for other hospital and medical			
	centive pool, withhold adjustments and bonus amounts			
16. S	ubtotal (Lines 9 to 15)			
	ess:			
	et reinsurance recoveries			
	otal hospital and medical (Lines 16 minus 17)			
	on-health claims (net)			
	laims adjustment expenses, including \$			
	ieneral administrative expenses	0		
22. lr	crease in reserves for life and accident and health contracts (including \$0			
	increase in reserves for life only)			
	otal underwriting deductions (Lines 18 through 22)			
	et underwriting gain or (loss) (Lines 8 minus 23)			
	et investment income earned (Exhibit of Net Investment Income, Line 17)			
	et realized capital gains (losses) less capital gains tax of \$			
	et investment gains (losses) (Lines 25 plus 26)	0		
28. N	et gain or (loss) from agents' or premium balances charged off [(amount recovered			
	\$0 ) (amount charged off \$0 )]	0	0	0
29. A	ggregate write-ins for other income or expenses	0		
30. N	et income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	XXX		
32. N	let income (loss) (Lines 30 minus 31)	XXX	140,113,520	134,476,909
	ETAILS OF WRITE-INS	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	,	,
0601.				.0
0602				
0603				
0698. S	ummary of remaining write-ins for Line 6 from overflow page		0	0
0699. T	otals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	XXX	0	0
0701.		XXX	0	0
0702		XXX		
0703		XXX		
0798. S	ummary of remaining write-ins for Line 7 from overflow page		0	0
	otals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	XXX	0	0
1401.		0	0	0
1402				
1403		0		n
	ummary of remaining write-ins for Line 14 from overflow page	0	0	U
	otals (Lines 1401 thru 1403 plus 1498)(Line 14 above)		49	90
2901. M				
2902				
	ummary of remaining write-ins for Line 29 from overflow page			
	otals (Lines 2901 thru 2903 plus 2998)(Line 29 above)	0	49	90

# **STATEMENT OF REVENUE AND EXPENSES (Continued)**

		1 Current Year	2 Prior Year
	CAPITAL AND SURPLUS ACCOUNT		
33.	Capital and surplus prior reporting year		
34.	Net income or (loss) from Line 32		
35.	Change in valuation basis of aggregate policy and claim reserves	0	0
36.	Change in net unrealized capital gains (losses) less capital gains tax of \$0		1,977,196
37.	Change in net unrealized foreign exchange capital gain or (loss)	0	0
38.	Change in net deferred income tax	2,794,843	2,816,657
39.	Change in nonadmitted assets	(10,688,748)	(4,209,897)
40	Change in unauthorized and certified reinsurance	0	0
41.	Change in treasury stock	0	0
42.	Change in surplus notes	0	0
43.	Cumulative effect of changes in accounting principles	0	0
44.	Capital Changes:		
	44.1 Paid in	0	0
	44.2 Transferred from surplus (Stock Dividend)	0	0
	44.3 Transferred to surplus.	0	0
45.	Surplus adjustments:		
	45.1 Paid in		
	45.2 Transferred to capital (Stock Dividend)	0	0
	45.3 Transferred from capital	0	0
46.	Dividends to stockholders	0	0
47.	Aggregate write-ins for gains or (losses) in surplus	0	0
48.	Net change in capital and surplus (Lines 34 to 47)		
49.	Capital and surplus end of reporting period (Line 33 plus 48)	879,045,229	716,768,438
	DETAILS OF WRITE-INS		
4701.		0	0
4702.			
4703.			
4798.	Summary of remaining write-ins for Line 47 from overflow page	0	0
4799.	Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	0	0

# **CASH FLOW**

		1	2
		Current Year	Prior Year
	Cash from Operations		
1.	Premiums collected net of reinsurance	5,471,597,596	4,351,275,375
2.	Net investment income		
3.	Miscellaneous income	0	(
4.	Total (Lines 1 through 3)	5,500,945,672	4,383,978,136
5.	Benefit and loss related payments		
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7.	Commissions, expenses paid and aggregate write-ins for deductions		
8.	Dividends paid to policyholders		
9.	Federal and foreign income taxes paid (recovered) net of \$1,006,957 tax on capital gains (losses)	61,415,067	39,814,424
10.	Total (Lines 5 through 9)		4,100,609,279
11.	Net cash from operations (Line 4 minus Line 10)		283,368,857
		242,004,120	200,000,001
	Cash from Investments		
12.	Proceeds from investments sold, matured or repaid:		
12.	12.1 Bonds	297 296 001	406 057 536
	12.2 Stocks		
	12.3 Mortgage loans		(
	12.4 Real estate		(
	12.5 Other invested assets		
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	12.7 Miscellaneous proceeds		(
	12.8 Total investment proceeds (Lines 12.1 to 12.7)		406,958,078
13.	Cost of investments acquired (long-term only):		
	13.1 Bonds		
	13.2 Stocks	0	(
	13.3 Mortgage loans	0	(
	13.4 Real estate		(
	13.5 Other invested assets		(
	13.6 Miscellaneous applications	5,000	(
	13.7 Total investments acquired (Lines 13.1 to 13.6)	560,776,566	711,824,925
14.	Net increase (decrease) in contract loans and premium notes	0	(
15.	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(170,684,858)	(304,866,847
16.	Cash from Financing and Miscellaneous Sources Cash provided (applied):		
	16.1 Surplus notes, capital notes		
	16.2 Capital and paid in surplus, less treasury stock		
	16.3 Borrowed funds	0	(
	16.4 Net deposits on deposit-type contracts and other insurance liabilities		
	16.5 Dividends to stockholders		
	16.6 Other cash provided (applied)		55,359,246
17.	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)		125,359,246
17.			123,003,240
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	81,008,255	103,861,256
	Cash, cash equivalents and short-term investments:		
19.		1	
19.	19.1 Beginning of year		

Τ

# ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		1	2	3	4	5	6 Federal	7	8	9	10
		Total (	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1.	Net premium income		0	0	0	0	0			0	0
	Change in unearned premium reserves and reserve for rate credit	0	0	0	0	0	0	0	(		0
3.	Fee-for-service (net of \$0 medical expenses)	0	0	0	0	0	0	0	(	0	XXX
4.	Risk revenue	0	0	0	0	0	0	0	(	0	XXX
		0		0		0					XXX
6.	Aggregate write-ins for other non-health care related revenues	0									0
7.	Total revenues (Lines 1 to 6)		0	0	0	0	0		(	0	0
8.	Hospital/medical benefits	3,947,399,906	0	0	0	0	0		(	0	XXX
9.	Other professional services			0	0	0			(	o [o [	XXX
10.	Outside referrals	0	0	0	.0	0	0		(	0	XXX
11.	Emergency room and out-of-area	.95,874,554	0	0	.0	0	0	.95,874,554	(	0	XXX
12.	Prescription drugs	269,593,289	0	0	.0	0	0	269,593,289	(	0	XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	.0	0	0		(	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts		0	0	.0	0	0		(	0	XXX
15.	Subtotal (Lines 8 to 14)	4,577,042,968	0	0	.0	0	0		(	0	XXX
16.	Net reinsurance recoveries	0	0	0	0	0	0	0	(	0	XXX
17.		4.577.042.968	0	0	0	0	0	4.577.042.968	(	0	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
19.	Claims adjustment expenses including \$	.169,390,602	0	0	0	0	0		(	0	0
20.	General administrative expenses	599,873,472	0	0	.0	0	0	599,873,472	(	0	0
21.		0	0	0	0	0	0	0	(	0	XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
23.	Total underwriting deductions (Lines 17 to 22)		0	0	0	0		5,346,307,041	(	0	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	167,494,594	0	0	0	0	0	167,494,594	(	0	0
0501.	DETAILS OF WRITE-INS	,					-	,		-	××××
											XXX XXX
0502. 0503.											
	Summary of remaining write-ins for Line 5 from overflow	0									
0500	page Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	U			U	V			ل ۱	V	
0599.	Totals (Lines 000 F third 0003 plus 0096) (Line 5 above)	U	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	~~~
0601. 0602.			XXX XXX		XXX XXX		XXX	XXX XXX		XXX XXX	
0602.			XXX XXX		XXX	XXX XXX	XXX	XXX			
		0					XXX			XXX	~
0699.	page Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	U 0	XXX XXX	XXX XXX	XXX XXX	XXX XXX				XXX XXX	
1301.											XXX
1302.											XXX
1303. 1398.	Summary of remaining write-ins for Line 13 from										XXX
1	overflow page	0	0	0	Q	0	0	0		٥٥	XXX
1399.	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	0	0	0	0	0	0	0	(	0	XXX

7

# UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMIUMS

	1	2	3	4
Line of Business	Direct Business	Reinsurance Assumed	Reinsurance Ceded	Net Premium Income (Cols. 1 + 2 - 3)
1. Comprehensive (hospital and medical)	0	0	0	0
2. Medicare Supplement	0	0	0	0
3. Dental only	0	0	0	0
	0	0	0	0
4. Vision only	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0
6. Title XVIII - Medicare	5,513,801,635	0	0	5,513,801,635
7. Title XIX - Medicaid	0	0	0	0
8. Other health	0	0	0	0
9. Health subtotal (Lines 1 through 8)	5,513,801,635	0	0	5,513,801,635
10. Life	0	0	0	0
11. Property/casualty	0	0	0	0
12. Totals (Lines 9 to 11)	5,513,801,635	0	0	5,513,801,635

# UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

	1	2 Comprehensive	3 Medicare	4	5	6 Federal Employees Health	7 Title XVIII	8 Title XIX	9	10 Other
	Total	(Hospital & Medical)	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Other Health	Non-Health
1. Payments during the year:										1
1.1 Direct	4,324,132,241	0	0	0	0	0	4,324,132,241	0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net	4,324,132,241	0	0	0	0	0	4,324,132,241	0	0	0
2. Paid medical incentive pools and bonuses		0	0	0	0	0		0	0	0
3. Claim liability December 31, current year from Part 2A:										1
3.1 Direct		0	0	0	0	0		0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net		0	0	.0	0	0		0	0	
4. Claim reserve December 31, current year from Part 2D:	, ,						, ,			1
4.1 Direct	0	0	0	0	0	0	0	0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	0	0	0	0	0	0	0	0	0	0
5. Accrued medical incentive pools and bonuses, current										
year		0	0	0	0	0		0	0	0
6. Net healthcare receivables (a)	19.583.938	0	0	0	0	0	19,583,938	0	0	0
7. Amounts recoverable from reinsurers December 31,	-,,						-,,			1
current year	0	0	0	0	0	0	0	0	0	0
8. Claim liability December 31, prior year from Part 2A:										1
8.1 Direct		0	0	0	0	0		0	0	0
8.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
8.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
8.4 Net		0	0	0	0	0		0	0	0
9. Claim reserve December 31, prior year from Part 2D:										
9.1 Direct	0	0	0	0	0	0	0	0	0	0
9.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	e
9.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
9.4 Net	0	0	0	0	0	0	0	0	0	
10. Accrued medical incentive pools and bonuses, prior year	61,497,322	0	0	0	0	0	61,497,322	0	0	0
11. Amounts recoverable from reinsurers December 31,	01, 107, 022	0	0	U	U	0	01,707,022	0	0	0
prior year	0	0	0	0	0	0	0	0	0	0
12. Incurred Benefits:	v			Ŭ	ů			Ū		
12.1 Direct		n	٥	٥	٥	0		٥	n	n
12.1 Direct					0			0 0		
12.2 Reinsurance ceded	0 		0	0	0 ^	0 		0 0	0	
12.3 Reinsurance ceded	4,495,024,650	0	0	0	0	0	4,495,024,650	0	0	
		0	0	0	0	0	4,495,024,650 82.018.318	0	0	
13. Incurred medical incentive pools and bonuses	82,018,318	U	U	U	U	0	82,018,318	U	0	(

(a) Excludes \$ .....0 loans or advances to providers not yet expensed.

# UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY END OF CURRENT YEAR

	1	2	3	4	5	6	7	8	9	10
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other Health	Other Non-Health
1. Reported in Process of Adjustment:										
1.1 Direct		0	0	0	0	0		0	0	0
1.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
1.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
1.4 Net		0	0	0	0	0		0	0	0
2. Incurred but Unreported:										
2.1 Direct		0	0	0	0	0		0	0	0
2.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
2.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
2.4 Net		0	0	0	0	0		0	0	0
3. Amounts Withheld from Paid Claims and Capitations:										
3.1 Direct		0	0	0	0	0		0	0	0
3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
3.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
3.4 Net		0	0	0	0	0		0	0	0
4. TOTALS:										
4.1 Direct		0	0	0	0	0		0	0	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0
4.3 Reinsurance ceded	0	0	0	0	0	0	0	0	0	0
4.4 Net	568,187,547	0	0	0	0	0	568, 187, 547	0	0	0

# UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D	uring the Year	Claim Reserve a December 31	nd Claim Liability of Current Year	5	6
Line of Business	1 On Claims Incurred Prior to January 1 of Current Year	2 On Claims Incurred During the Year	3 On Claims Unpaid December 31 of Prior Year	4 On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Estimated Claim Reserve and Claim Liability December 31 of Prior Year
1. Comprehensive (hospital and medical)	0	0	0	0	0	0
2. Medicare Supplement	0	0	0	0	0	0
3. Dental Only	0	0	0	0	0	0
4. Vision Only	0	0	0	0	0	0
5. Federal Employees Health Benefits Plan	0	0	0	0	0	0
6. Title XVIII - Medicare		4,020,353,607	5,945,195			
7 Title XIX - Medicaid	0	0	0	0	0	0
8. Other health	0	0	0	0	0	0
9. Health subtotal (Lines 1 to 8)		4,020,353,607	5,945,195			
10. Healthcare receivables (a)			0	0		
11. Other non-health	0	0	0	0	0	0
12. Medical incentive pools and bonus amounts		0	2,464,381			
13. Totals (Lines 9 - 10 + 11 + 12)	355,165,415	3,923,725,077	8,409,576	650,990,074	363,574,992	361,247,174

(a) Excludes \$ ......0 loans or advances to providers not yet expensed.

1

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

#### (\$000 Omitted)

#### Section A - Paid Health Claims - Title XVIII

	Cumulative Net Amounts Paid					
	1	2	3	4	5	
Year in Which Losses Were Incurred	2016	2017	2018	2019	2020	
1. Prior	6,576					
2. 2016						
3. 2017	XXX					
4. 2018	XXX		2,635,321		2,846,913	
5. 2019			XXX		3,690,948	
6. 2020	XXX	XXX	XXX	XXX	4,020,354	

eserve and Medical Incentive Year	Pool and Bonuses
Year	
4	5
2019	2020
	2,847,234
XXX	4,671,344
31 12	314

#### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10
	Years in which					Claim and Claim Adjustment Expense			Unpaid Claims	Total Claims and Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	2016				1.0			0	0		.94.9
2	. 2017			6,822				0	0		
3	. 2018										
4	. 2019				1.0						
5	. 2020	5,513,802	4,020,354	38,234	1.0	4,058,588	73.6	650,990	3,915	4,713,493	85.5

# **UNDERWRITING AND INVESTMENT EXHIBIT**

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS

## (\$000 Omitted)

#### Section A - Paid Health Claims - Grand Total

		Cumulative Net Amounts Paid				
	1	2	3	4	5	
Year in Which Losses Were Incurred	2016	2017	2018	2019	2020	
1. Prior						
2. 2016						
3. 2017						
4. 2018		XXX			2,846,913	
5. 2019		XXX				
6. 2020	XXX	XXX	XXX	XXX	4,020,354	

	Sum of Cumulative Net	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu Outstanding at End of Year					
Year in Which Losses Were Incurred	1 2016	2 2017	3 2018	4 2019	5 2020		
1. Prior		6,775			<u>6,707</u>		
2. 2016							
3. 2017							
4. 2018		XXX			2,847,234		
5. 2019			XXX				
6. 2020	XXX	XXX	XXX	XXX	4,671,344		

#### Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	. 2016							0	0		
2	2. 2017				1.0			0	0		
3	3. 2018	3,417,678									
4	. 2019	4,345,828									
5	5. 2020	5,513,802	4,020,354	38,234	1.0	4,058,588	73.6	650,990	3,915	4,713,493	85.5

# UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	1	2	3	4	5	6	7	8	9
	Total	Comprehensive (Hospital & Medical)	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Other
1. Unearned premium reserves	0	0	0	0	0	0	0	0	0
2. Additional policy reserves (a)	0	0	0	0	0	0	0	0	0
3. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
4. Reserve for rate credits or experience rating refunds (including									
\$0 ) for investment income		0	0	0	0	0	1,937,486	0	0
5. Aggregate write-ins for other policy reserves	10,089,631	0	0	0	0	0		0	0
6. Totals (gross)		0	0	0	0	0		0	0
7. Reinsurance ceded	0	0	0	0	0	0	0	0	0
8. Totals (Net)(Page 3, Line 4)		0	0	0	0	0		0	0
9. Present value of amounts not yet due on claims	0	0	0	0	0	0	0	0	0
10. Reserve for future contingent benefits	0	0	0	0	0	0	0	0	0
11. Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0
12. Totals (gross)	0	0	0	0	0	0	0	0	0
13. Reinsurance ceded	0	0	0	0	0	0	0	0	0
14. Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0
DETAILS OF WRITE-INS 0501. Risk Adjustment Premium Payable		0	0	0	0	0		0	0
0503.									
0598. Summary of remaining write-ins for Line 5 from overflow page	0	0	0	0	0	0	0	0	0
0599. Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	10,089,631	0	0	0	0	0	10,089,631	0	0
1101									
1102.									
1103.									
1198. Summary of remaining write-ins for Line 11 from overflow page	0	0	0	0	0	0	0	0	0
1199. Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0

(a) Includes \$ \_\_\_\_\_0 premium deficiency reserve.

# UNDERWRITING AND INVESTMENT EXHIBIT

		Claim Adjustme	YSIS OF EXPENSE ent Expenses	3	4	5
		1 Cost Containment Expenses	2 Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$0 for occupancy of					
	own building)					
2.	Salary, wages and other benefits					
3.	Commissions (less \$0					
	ceded plus \$0 assumed)	0	0			
4.	Legal fees and expenses					
5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses					
8.	Marketing and advertising					
9.	Postage, express and telephone					
10.	Printing and office supplies					
11.	Occupancy, depreciation and amortization					
12.	Equipment					
13.	Cost or depreciation of EDP equipment and					
	software	2,643,202		9,011,886	(16,599)	
14.	Outsourced services including EDP, claims, and other services	52 252 088	8 267 020	100 850 749	195 610	161 566 376
15.	Boards, bureaus and association fees					
	Insurance, except on real estate					1,476,861
16.	Collection and bank service charges					
17.	-					
18.	Group service and administration fees					6,084,814
19.	Reimbursements by uninsured plans					
20.						
21.	Real estate expenses					
22.		0	0	0	0	0
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes					
	23.2 State premium taxes					
	23.3 Regulatory authority licenses and fees					
	23.4 Payroll taxes	0	0			10,047,629
	23.5 Other (excluding federal income and real estate taxes)	0	0			
24.	Investment expenses not included elsewhere				(786)	
25.	Aggregate write-ins for expenses		51,995	2,677,475	450	2,967,877
26.	Total expenses incurred (Lines 1 to 25)		,		696.846 (2	a)
27.	Less expenses unpaid December 31, current year				·	
28.	Add expenses unpaid December 31, prior year				0	
20.	Amounts receivable relating to uninsured plans,		2,240,000	12,400,000		
23.	prior year	0	0	3,693,675	0	3,693,675
30.	Amounts receivable relating to uninsured plans, current year	0	0	33,442,902	0	33,442,902
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	143,263,369	24,402,127	634,628,921	696,846	802,991,262
	DETAILS OF WRITE-INS					
2501.	Miscellaneous Administrative Expenses			2,677,475		2,967,877
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	237,957	51.995	2,677,475	450	2,967,877

# ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Arcadian Health Plan Inc. EXHIBIT OF NET INVESTMENT INCOME

			1		2
		Colle	cted During Year	Earne	d During Year
1.	U.S. government bonds	(a)			
1.1	Bonds exempt from U.S. tax	(a)	0		0
1.2	Other bonds (unaffiliated)	(a)			21,941,718
1.3	Bonds of affiliates	(a)	0		0
2.1	Preferred stocks (unaffiliated)	(b)	0		0
2.11	Preferred stocks of affiliates	(b)	0		0
2.2	Common stocks (unaffiliated)		0		0
2.21	Common stocks of affiliates		0		0
3.	Mortgage loans		0		0
4.	Real estate	(d)	0		0
5	Contract Loans		0		0
6	Cash, cash equivalents and short-term investments	(e)	3,544,490		3,483,278
7	Derivative instruments		0		0
8.	Other invested assets		0		0
9.	Aggregate write-ins for investment income				
10.	Total gross investment income		25,062,980		25,861,752
11.	Investment expenses			(g)	
12.	Investment taxes, licenses and fees, excluding federal income taxes			(g)	
13.	Interest expense			(h)	0
14.	Depreciation on real estate and other invested assets			(i)	0
15.	Aggregate write-ins for deductions from investment income				0
16.	Total deductions (Lines 11 through 15)				
17.	Net investment income (Line 10 minus Line 16)				25,164,906
	DETAILS OF WRITE-INS				
0901.	Miscellaneous Investment Income				
0902.					
0903.					
0998.	Summary of remaining write-ins for Line 9 from overflow page		0		0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)		8,722		8,722
1501.					
1502.					
1503.					
1598.	Summary of remaining write-ins for Line 15 from overflow page				0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)				0

(a) Includes \$
(b) Includes \$
(c) Includes \$
(d) Includes \$
(e) Includes \$
(f) Includes \$
(g) Includes \$
(h) Includes \$0 interest on surplus notes and \$0 interest on capital notes.
(i) Includes \$

# EXHIBIT OF CAPITAL GAINS (LOSSES)

		1	2	3	4	5
				THERE	0	
		Dealized Onia (Leas)	Other Deelined	Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds		0		0	0
1.1	Bonds exempt from U.S. tax		0			0
1.2	Other bonds (unaffiliated)		0	9,484,053		0
1.3	Bonds of affiliates	0	0	0	0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates	0	0	0	0	0
2.2	Common stocks (unaffiliated)	0	0	0	0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans	0	0	0	0	0
4.	Real estate	0	0	0	0	0
5.	Contract loans		0	0	0	0
6.	Cash, cash equivalents and short-term investments		0		0	0
7.	Derivative instruments		0	0	0	0
8.	Other invested assets	0	0	0		0
9.	Aggregate write-ins for capital gains (losses)		0 0	0	0	0
-		0 506 747	0	0 506 747		0
10.	Total capital gains (losses)	9,506,747	0	9,506,747	57,176	U
	DETAILS OF WRITE-INS					
0901.						
0902.						
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
	above)	0	0	0	0	0

# EXHIBIT OF NON-ADMITTED ASSETS

			2	3
		Current Year Total Nonadmitted Assets	Prior Year Total Nonadmitted Assets	Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)	0	0	0
2.	Stocks (Schedule D):			
	2.1 Preferred stocks	0	0	0
	2.2 Common stocks	0	0	0
3.	Mortgage loans on real estate (Schedule B):			
	3.1 First liens	0	0	0
	3.2 Other than first liens			0
4.	Real estate (Schedule A):			
	4.1 Properties occupied by the company	0	0	0
	4.2 Properties held for the production of income		0	0
	4.3 Properties held for sale		0	0
5.	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments (Schedule DA)		0	
6.	Contract loans	0	0	0
7.	Derivatives (Schedule DB)	0	0	0
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities		0	
10.	Securities lending reinvested collateral assets (Schedule DL)		0	
11.	Aggregate write-ins for invested assets		0	0
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			0
15.	Premiums and considerations:			
10.	15.1 Uncollected premiums and agents' balances in the course of collection	1 596 121	1 510 451	(85,670)
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
10.	16.1 Amounts recoverable from reinsurers	0	0	0
	16.2 Funds held by or deposited with reinsured companies			0
	16.3 Other amounts receivable under reinsurance contracts			
17	Amounts receivable relating to uninsured plans			
				0
	Current federal and foreign income tax recoverable and interest thereon			
	Net deferred tax asset			. , ,
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software		0	0
21.	Furniture and equipment, including health care delivery assets		0	0
22.	Net adjustment in assets and liabilities due to foreign exchange rates		0	0
23.	Receivable from parent, subsidiaries and affiliates		0	0
24.	Health care and other amounts receivable		6,535,425	
25.	Aggregate write-ins for other than invested assets			(7,201,070)
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)		23,582,076	
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts		0	0
28.	Total (Lines 26 and 27)	34,270,823	23,582,076	(10,688,748)
1101.	DETAILS OF WRITE-INS	0	0	0
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above)	0	0	0
2501.	Prepaid Commissions	10,710,045		(1,753,144)
2502.	Provider Contracts			(853,881)
2503.	Prepaid Expenses		0	(4,665,660)
2598.	Summary of remaining write-ins for Line 25 from overflow page			
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	22,203,537	15,002,467	,

# EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

			Ţ	otal Members at End o	f		6
		1	2	3	4	5	Current Year
	Source of Enrollment	Prior Year	First Quarter	Second Quarter	Third Quarter	Current Year	Member Months
1.	Health Maintenance Organizations						4,980,739
2.	Provider Service Organizations	0	0	0	0	0	0
3.	Preferred Provider Organizations						
4.	Point of Service	0	0	0	0	0	0
5.	Indemnity Only	0	0	0	0	0	0
6.	Aggregate write-ins for other lines of business	0	0	0	0	0	0
7.	Total	385,108	421,276	428,914	440,520	445,510	5,179,311
	DETAILS OF WRITE-INS						
0601.							
0602.							
0603.							
0698.	Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699.	Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	0	0	0	0	0	0

# NOTES TO THE FINANCIAL STATEMENTS

#### 1. <u>Summary of Significant Accounting Policies and Going Concern</u>

#### A. Accounting Practices

The financial statements of the Company are presented on the basis of accounting practices prescribed or permitted by the Washington Office of Insurance.

The Washington Office of Insurance (the Office) recognizes only statutory accounting practices prescribed or permitted by the State of Washington for determining and reporting the financial condition and results of operations of an insurance company, for determining its solvency under the Washington Insurance Law. The National Association of Insurance Commissioners' (NAIC) Accounting Practices and Procedures manual (NAIC SSAP) has been adopted as a component of prescribed or permitted practices by the State of Washington. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices. No deviations from the Codification currently exist.

A reconciliation of the Company's net income and capital and surplus between NAIC SSAP and practices prescribed and permitted by the State of Washington is shown below:

	SSAP #	F/S Page	F/S Line #	_	2020		2019
Net Income				_		_	
1. Arcadian Health Plan, Inc.	XXX	XXX	XXX	\$	140,113,520	\$	134,476,909
Washington basis							
2. State Prescribed Practices that is							
an increase/(decrease) NAIC					-		-
SSAP							
3. State Permitted Practices that is an							
increase/(decrease) NAIC SSAP				-	-		-
4. NAIC SSAP	XXX	XXX	XXX	\$	140,113,520	\$	134,476,909
Surplus							
<ol> <li>Arcadian Health Plan, Inc. Washington basis</li> </ol>	XXX	XXX	XXX	\$	879,045,229	\$	716,768,438
6. State Prescribed Practices that is							
an increase/(decrease) NAIC					-		-
SSAP							
7. State Permitted Practices that is an							
increase/(decrease) NAIC SSAP					-		-
8. NAIC SSAP	XXX	XXX	XXX	\$_	879,045,229	\$_	716,768,438

#### B. Use of Estimates in the Preparation of the Financial Statements

The preparation of financial statements in conformity with Statutory Accounting Principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. It also requires disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the period. These estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results could differ from those estimates.

C. Accounting Policy

Premiums are reported as earned in the period in which members are entitled to receive services, and are net of retroactive membership adjustments. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by an employer group or the government. Premiums received prior to such period are recorded as advance premiums.

Benefits incurred and loss adjustment expenses include claim payments, capitation payments, pharmacy costs net of rebates, allocations of certain centralized expenses, legal and administrative costs to settle claims, and various other costs incurred to provide health insurance coverage to members, as well as estimates of future payments to hospitals and others for medical care provided prior to the date of the statements of admitted assets, liabilities and surplus. Capitation payments represent monthly contractual fees disbursed to participating primary care physicians, and other providers who are responsible for providing medical care to members. Pharmacy costs represent payments for members' prescription drug benefits, net of rebates from drug manufacturers.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments mainly in U.S. Government obligations with a maturity of twelve months or less from the date of purchase. Short-term investments are recorded at amortized cost. The carrying value of short-term investments approximates fair value due to the short-term maturities of the investments.
- (2-4) Investments are valued and classified in accordance with methods prescribed by the NAIC. Bonds with an NAIC rating of 1 or 2 are carried at amortized cost, with all other bonds being recorded at the lower of amortized cost or fair value; redeemable preferred stocks are carried at amortized cost; and non-redeemable preferred stocks are carried at fair value.

The Company regularly evaluates investment securities for impairment. For all securities other than loanbacked and structured securities, the Company considers factors affecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value, the near term prospects for recovery to carrying value, and the Company's intent and ability to hold the investment until maturity or market recovery is realized. If and when a determination is made that a decline in fair value below the cost basis is other-thantemporary, the related investment is written down to its estimated fair value through earnings.

Amortization of bond premium or discount is computed using the scientific interest method.

Income from investments is recorded on an accrual basis. For the purpose of determining realized gains and losses, the cost of securities sold is based upon specific identification. Investment income due and accrued over 90 days past due is nonadmitted.

- (5) Not Applicable.
- (6) For loan backed and structured securities where the securities fair value is less than the amortized cost, the Company considers several factors to determine if the security's impairment is other-than-temporary. If the Company has the intent to sell the security or if the Company does not have the intent and ability to retain the security until recovery of its fair value, the related investment is written down to its estimated fair value through earnings. If, however, the Company has the intent and ability to retain the security until recovery of its fair safecting the investee, factors affecting the industry the investee operates within, and general debt and equity market trends. The Company also considers the length of time an investment's fair value has been below carrying value and the near term prospects for recovery to carrying value. If the determination is made, based on these factors, that the Company does expect to recover the entire amortized cost of the security, then an other-than-temporary impairment has not occurred. If, however, the determination is made that the Company does not expect to recover the entire amortized cost of the security based on the factors noted above, the Company recognizes a realized loss in earnings for the non-interest related decline. No loss is recognized for the interest impairment.
- (7) Not Applicable.
- (8) Not Applicable.
- (9) Not Applicable.
- (10-11) The estimates of future medical benefit payments are developed using actuarial methods and assumptions based upon claim payment patterns, medical cost inflation, historical development such as claim inventory levels and claim receipt patterns, and other relevant factors. Corresponding administrative costs to process outstanding claims are estimated and accrued. Estimates of future payments relating to services incurred in the current and prior periods are continually reviewed by management and adjusted as necessary.

The Company assesses the profitability of its contracts for providing health insurance coverage to its members when current operating results or forecasts indicate probable future losses. The Company records a premium deficiency liability in current operations to the extent that the sum of expected future medical costs, claim adjustment expenses and maintenance costs exceed related future premiums. Investment income is not contemplated in the calculation of the premium deficiency liability.

Management believes the Company's benefits payable and loss adjustment expense are adequate to cover future claims and loss adjustment expense payments required, however, such estimates are based on knowledge of current events and anticipated future events and, therefore, the actual liability could differ from the amounts provided.

(12) The Company has not modified its capitalization policy from the prior period.

Equipment is stated at cost less accumulated depreciation. Depreciation expense is computed using the straightline method over estimated useful lives generally ranging from three to five years. Improvements to leased facilities are depreciated over the shorter of the remaining lease term or the anticipated life of the improvement.

The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax basis of assets or liabilities and their reported amounts in the financial statements. The temporary differences will result in taxable or deductible amounts in future years when the reported amounts of the assets or liabilities are recovered or settled.

- (13) The Company estimates anticipated Pharmacy Rebate Receivables using the analysis of historical recovery patterns.
- (14) Not Applicable.
- (15) Not Applicable.
- D. Going Concern

Management of the Company has evaluated the Company's ability to continue as a going concern under SSAP No. 1, *Accounting Policies, Risks & Uncertainties, and Other Disclosures* (SSAP No. 1). Based on this evaluation, Management has determined that there is no substantial doubt about the Company's ability to continue as a going concern.

2. Accounting Changes and Corrections of Errors

Not Applicable.

- 3. Business Combinations and Goodwill
  - A. Statutory Purchase Method

Not Applicable.

B. Statutory Merger

Not Applicable.

C. Assumption Reinsurance

Not Applicable.

D. Impairment Loss

Not Applicable.

4. Discontinued Operations

Not Applicable.

## 5. <u>Investments</u>

A. Mortgage Loans, Including Mezzanine Real Estate Loans

Not Applicable.

B. Debt Restructuring

Not Applicable.

C. Reverse Mortgages

Not Applicable.

- D. Loan-Backed Securities
  - (1) Prepayment assumptions for mortgage-backed/loan-backed and structured securities were obtained from industry market sources.
  - (2) Not Applicable.
  - (3) Not Applicable.
  - (4) The Company does not have any investments in an other-than-temporary impairment position at December 31, 2020.

Gross unrealized losses and related fair value of temporarily impaired securities that have been in a continuous unrealized loss position were as follows at December 31, 2020:

(a) The aggregate amount of unrealized losses:

1.	Less than Twelve Months	\$ (195,202)
2.	Twelve Months or Longer	\$ (33,244)

(b) The aggregate related fair value of securities with unrealized losses:

1.	Less than Twelve Months	\$ 57,666,199
2.	Twelve Months or Longer	\$ 15,161,756

- (5) Unrealized losses are primarily due to increases in market interest rates and tighter liquidity conditions in the current markets than when the securities were purchased. All issuers of securities trading at an unrealized loss remain current on all contractual payments and the Company believes it is probable that all amounts due according to the contractual terms of the debt securities are collectible. After taking into account these and other factors, including the severity of the decline and the Company's ability and intent to hold these securities until recovery or maturity, the Company determined the unrealized losses on these investment securities were temporary and, as such, no impairment was required.
- E. Dollar Repurchase Agreements and/or Securities Lending Transactions
  - (1) The Company has no repurchase agreements or securities lending transactions.
  - (2) The Company has not pledged any of its assets as collateral.
  - (3-7) Not Applicable.
- F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

Not Applicable.

H. Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

Not Applicable.

J. Real Estate

Not Applicable.

K. Low-Income Housing Tax Credits (LIHTC)

Not Applicable.

- L. Restricted Assets
  - (1) Restricted Assets (Including Pledged)

	1	2	3	4	5	6 Percentage	7 Percentage
Restricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross (Admitted & Nonadmitted) Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a. Subject to contractual							
obligation for which	¢	<i>.</i>	¢	<i>.</i>	<b>.</b>	<i></i>	<b>0</b> (
liability is not shown b. Collateral held under	\$ -	\$ -	\$ -	\$ -	\$ -	-%	-%
security lending							
agreements	-	-	-	-	-	-	-
c. Subject to repurchase							
agreements	-	-	-	-	-	-	-
d. Subject to reverse							
repurchase agreements	-	-	-	-	-	-	-
e. Subject to dollar							
repurchase agreements	-	-	-	-	-	-	-
f. Subject to dollar reverse repurchase agreements							
g. Placed under option	-	-	-	-	-	-	-
contracts	-	-	-	-	-	-	-
h. Letter stock or securities							
restricted to sale -							
excluding FHLB							
capital stock	-	-	-	-	-	-	-
i. FHLB capital							
stock j. On deposit with states	11,601,925	12,318,518	(716,593)	-	- 11,601,925	- 0.71%	0.73%
k. On deposit with other	11,001,923	12,516,516	(710,393)	-	11,001,923	0.7170	0.7376
regulatory bodies	_	-	-	-	-	-	-
1. Pledged collateral to							
FHLB (including							
assets backing funding							
agreements)	-	-	-	-	-	-	-
m. Pledged as collateral not							
captured in other							
categories n. Other restricted assets	-	-	-	-	-	-	-
n. Other restricted assets		-	-	-	-	-	
o. Total Restricted Assets	\$ 11,601,925	\$ 12,318,518	\$ (716,593)	-	\$ 11,601,925	0.71%	0.73%

(2) Detail of Assets Pledged as Collateral Not Captured in Other Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(3) Detail of Other Restricted Assets Categories (Contracts that Share Similar Characteristics, Such as Reinsurance and Derivatives, Are Reported in the Aggregate)

Not Applicable.

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

Not Applicable.

M. Working Capital Finance Investments

Not Applicable.

N. Offsetting and Netting of Assets and Liabilities

Not Applicable.

O. 5GI\* Securities

Not Applicable.

P. Short Sales

Not Applicable.

- Q. Prepayment Penalty and Acceleration Fees
  - (1) Number of CUSIPS 1 4,986
- (2) Aggregate Amount of Investment Income \$
- 6. Joint Ventures, Partnerships and Limited Liability Companies
  - The Company has no investments in Joint Ventures, Partnerships or Limited Liability Companies that exceed 10.0 percent Α. of its admitted assets.
  - The Company did not recognize any impairment write down for its investments in Joint Ventures, Partnerships and B. Limited Liability Companies during the statement periods.

#### 7. Investment Income

A. Due and accrued income was excluded from surplus on the following basis:

All investment income due and accrued with amounts that are over 90 days past due with the exception of mortgage loans in default.

B. The total amount excluded was \$0.

#### 8. Derivative Instruments

Not Applicable.

#### 9. Income Taxes

- A. Deferred Tax Assets/(Liabilities)
  - (1) The components of the net admitted deferred tax asset/(liability) by tax character were as follows:

			ecen	ber 31, 2020	
		 Ordinary		Capital	Total
a.	Gross deferred tax assets	\$ 11,058,818	\$	1,350	\$ 11,060,168
b.	Statutory valuation allowance adjustments	-		(1,350)	(1,350)
c.	Adjusted gross deferred tax assets	 11,058,818		-	11,058,818
d.	Deferred tax assets nonadmitted	(708,621)		-	(708,621)
e.	Net admitted deferred tax assets	 10,350,197		-	10,350,197
f.	Deferred tax liabilities	(45,645)		-	(45,645)
g.	Net admitted deferred tax asset/(liability)	\$ 10,304,552	\$	-	\$ 10,304,552
		D	ecen	nber 31, 2019	
		Ordinary		Capital	Total
a.	Gross deferred tax assets	\$ 8,271,943	\$	13,378	\$ 8,285,321
b.	Statutory valuation allowance adjustments	-		(13,378)	(13,378)

\$

b.	Statutory valuation allowance adjustments	

- Adjusted gross deferred tax assets c.
- d. Deferred tax assets nonadmitted
- Net admitted deferred tax assets e.
- f. Deferred tax liabilities

a. b.

c.

d.

e. f.

g.

a.

b.

1. A

2.

c.

d. D

g. Net admitted deferred tax asset/(liability)

		(	Change	
	Ordinary		Capital	Total
Gross deferred tax assets	\$ 2,786,875	\$	(12,028)	\$ 2,774,847
Statutory valuation allowance adjustments	-		12,028	12,028
Adjusted gross deferred tax assets	 2,786,875		-	2,786,875
Deferred tax assets nonadmitted	(174,889)		-	(174,889)
Net admitted deferred tax assets	 2,611,986		-	2,611,986
Deferred tax liabilities	7,968		-	7,968
Net admitted deferred tax asset/(liability)	\$ 2,619,954	\$	-	\$ 2,619,954

8,271,943

(533,732)

7.738.211

(53.613)

7.684.598

\$

8,271,943

(533,732)

7.738.211

(53,613)

7.684.598

\_

\$

The amount of admitted adjusted gross deferred tax assets under SSAP No. 101 were as follows: (2)

		Ordinary	Capital	Total
Federal income taxes paid in prior years recoverable through loss carrybacks	\$	10,103,801	\$ - \$	10,103,801
Adjusted gross deferred tax assets expected to be realized after application of the threshold limitation		200.751	-	200.751
Adjusted gross deferred tax assets expected to be realized following the Balance Sheet		,.		
date		XXX	XXX	200,751
Adjusted gross deferred tax assets allowed per limitation threshold		XXX	XXX	130,311,102
Adjusted gross deferred tax assets offset by gross deferred tax liabilities		45,645	_	45,645
Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$	10,350,197	\$ - \$	10,350,197

		Ordinary	Dece	ember 31, 201 Capital	9	Total
a.	Federal income taxes paid in prior years recoverable through loss carrybacks Adjusted gross deferred tax assets expected	\$ 7,518,467	\$	-	\$	7,518,467
b. 1.	to be realized after application of the threshold limitation Adjusted gross deferred tax assets expected	166,131		-		166,131
2.	to be realized following the Balance Sheet date Adjusted gross deferred tax assets allowed	XXX		XXX		166,131
2.	per limitation threshold	XXX		XXX		106,362,576
c.	Adjusted gross deferred tax assets offset by gross deferred tax liabilities	 53,613		-		53,613
d.	Deferred tax assets admitted as the result of application of SSAP No. 101. Total	\$ 7,738,211	\$	-	\$	7,738,211
		Ordinary		Change Capital		Total
a.	Federal income taxes paid in prior years recoverable through loss carrybacks	\$ 2,585,334	\$	-	\$	2,585,334
b. 1.		34,620		-		34,620
	to be realized following the Balance Sheet date	XXX		XXX		34,620
2.	Adjusted gross deferred tax assets allowed per limitation threshold	XXX		XXX		23,948,526
c.	Adjusted gross deferred tax assets offset by gross deferred tax liabilities	(7,968)		-		(7,968)

(22)	
633%	655%
,740,677 709	9,083,839
,	

(4) The impact of tax planning strategies on adjusted gross DTAs and net admitted DTAs was as follows:

			Decem	ber 31,	2020
			Ordinary		Capital
a. 1	Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage				
1.	J	\$	11,058,818	\$	-
2.	attributable to the impact of tax planning strategies		0.00%		0.00%
5.	Net admitted adjusted gross DTAs amount from note 9A1(e)	\$	10,350,197	\$	-
4.		Ψ	10,550,177	Ψ	
	strategies		0.00%		0.00%
			Dagam	21	2010
			Decem	ber 31, 1	2019
			Ordinary	ber 31,	2019 Capital
a.	Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage			ber 31,	
a. 1.	admitted deferred tax assets, by tax character as a percentage	\$		\$	
	admitted deferred tax assets, by tax character as a percentage Adjusted gross DTAs amount from note 9A1(c)	\$	Ordinary		
1.	admitted deferred tax assets, by tax character as a percentage Adjusted gross DTAs amount from note 9A1(c) Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies	\$	Ordinary 8,271,943		Capital -
1. 2.	admitted deferred tax assets, by tax character as a percentage Adjusted gross DTAs amount from note 9A1(c) Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies Net admitted adjusted gross DTAs amount from note 9A1(e)	Ŧ	Ordinary 8,271,943 0.00%	\$	Capital -

	Change			
		Ordinary	-	Capital
a. Determination of adjusted gross deferred tax assets and net admitted deferred tax assets, by tax character as a percentage				
1. Adjusted gross DTAs amount from note 9A1(c)	\$	2,786,875	\$	-
<ol> <li>Percentage of adjusted gross DTAs by tax character attributable to the impact of tax planning strategies</li> <li>Net admitted adjusted gross DTAs amount from note</li> </ol>		0.00%		0.00%
9A1(e)	\$	2,611,986	\$	-
4. Percentage of net admitted adjusted gross DTAs by tax character admitted because of the impact of tax planning strategies		0.00%		0.00%

b. Does the Company's tax planning strategies include the use of reinsurance? Yes [ ] No [ X ]

B. There are no temporary differences for which a DTL has not been established.

## C. Current and deferred income taxes

(1) Current income taxes incurred consist of the following major components:

		December 31, 2020	December 31, 2019	Change	
a.	Federal	\$ 59,852,803	\$ 37,596,118	\$ 22,256,685	;
b.	Foreign	 -	-	-	
c.	Subtotal	59,852,803	37,596,118	22,256,685	i
d.	Federal income tax on net capital gains	2,200,822	640,341	1,560,481	
e.	Utilization of capital loss carryforwards	-	-	-	
f.	Other	(849)	(202,413)	201,564	,
g.	Federal and foreign income taxes incurred	\$ 62,052,776	\$ 38,034,046	\$ 24,018,730	)

(2–3) The tax effects of temporary differences that give rise to significant portions of the deferred tax assets and deferred tax liabilities are as follows:

DTAs resulting from Book/Tax Differences in:

a.	Ordinary		December 31, 2020	December 31, 2019	Change
	1. Discounting of unpaid losses	\$	7,060,002	\$ 5,828,439 \$	1,231,563
	2. Unearned premium reserve		152,148	61,544	90,604
	3. Policyholder reserves		-	-	-
	4. Investments and other		-	-	-
	5. Deferred acquisition costs		-	-	-
	6. Policyholder dividends accrual		-	-	-
	7. Fixed assets		-	-	-
	<ol> <li>Compensation and benefit accruals</li> </ol>		1,083	1,943	(860)
	9. Pension accruals		1,005	-	(000)
	10. Receivables – nonadmitted		-	-	_
	11. Net operating loss carry-forward			-	_
	12. Tax credit carry-forward		_	-	-
	13. Other		1,392	-	1,392
	14. Bad debts		1,730,308	1,030,636	699,672
	15. Accrued litigation			-	
	16. CMS Rx reserve		476,107	76,603	399,504
	17. CMS risk corridor -ACA		-	-	
	18. Medicare risk adjustment data		-	_	_
	19. Miscellaneous reserves		203,933	18,248	185,685
	20. Accrued lease			-	-
	21. Section 197 intangible		-	-	-
	22. Reinsurance fee		-	-	-
	23. Provider contracts		1,433,845	1,254,530	179,315
	24. Premium acquisition expense		-	-,,	
	99. Subtotal		11,058,818	8,271,943	2,786,875
b.	Statutory valuation allowance adjustment			-	_,
c.	Nonadmitted		(708,621)	(533,732)	(174,889)
d.	Admitted Ordinary DTAs		10,350,197	7,738,211	2,611,986
e.	Capital		10,000,177	1,700,211	2,011,200
	1. Investments		1,350	13,378	(12,028)
	2. Net capital loss carry-forward		-	-	-
	3. Real estate		-	-	-
	4. Other		-	-	-
	99. Subtotal		1,350	13,378	(12,028)
f.	Statutory valuation allowance adjustment		(1,350)	(13,378)	12,028
g.	Nonadmitted				
h.	Admitted capital DTAs	-	-	-	-
i.	Admitted DTAs	\$	10,350,197	\$ 7,738,211 \$	2,611,986

DTLs resulting from Book/Tax Differences in:

	a.	Ordinary	_	December 31, 2020	December 31, 2019	Change
		1. Investments	\$	-	\$ - \$	-
		<ol> <li>Fixed assets</li> <li>Deferred and uncollected</li> </ol>		-	-	-
		premium 4. Policyholder reserves/salvage & subrogation		-	-	-
		5. Other		-	-	-
		6. Premium acquisition reserve		(1,334)	(439)	(895)
		7. CMS Rx reserve		-	-	-
		8. Reserve transition adjustment		(44,311)	(53,174)	8,863
		99. Subtotal		(45,645)	(53,613)	7,968
	b.	Capital				
		1. Investments		-	-	-
		2. Real estate		-	-	-
		3. Other		-	-	-
		99. Subtotal		-	-	-
	c.	DTLs	\$	(45,645)	\$ (53,613) \$	7,968
(4)	Net	t deferred tax asset/(liability)	\$	10,304,552	\$ 7,684,598 \$	2,619,954

D. The provision for federal income taxes incurred is different from that which would be obtained by applying the statutory Federal income tax rate to income before income taxes. The significant items causing this difference as of December 31, 2020 are as follows:

			Effective Tax
	 Amount	Tax Effect	Rate
Income before taxes	\$ 202,166,296	\$ 42,454,922	21.00%
Tax-exempt interest	(1,057,255)	(222,024)	(0.12%)
Dividends received deduction	-	-	0.00%
Proration	264,314	55,506	0.03%
Meals & entertainment, lobbying expenses, etc.	447	94	0.00%
Statutory valuation allowance adjustment	-	-	0.00%
ACA Fee Change to nonadmitted assets & deferred tax	91,320,689	19,177,345	9.49%
true-up	(10,513,857)	(2,207,910)	(1.09%)
Other, including prior year true-up	 -	-	0.00%
Total	\$ 282,180,634	\$ 59,257,933	29.31%
Federal income taxes incurred			
[expense/(benefit)]		\$ 59,851,954	29.61%
Tax on capital gains/(losses) Change in net deferred income tax		2,200,822	1.09%
[charge/(benefit)]		 (2,794,843)	(1.39%)
Total statutory income taxes		\$ 59,257,933	29.31%

E. Operating loss and tax credit carry-forwards and protective tax deposits

(1) At December 31, 2020, the Company had no net operating loss carry-forwards.

At December 31, 2020, the Company had no capital loss carry-forwards.

At December 31, 2020, the Company had no AMT credit carry-forwards.

(2) The following table demonstrates the income tax expense for 2019 and 2020 that is available for the recoupment in the event of future net losses:

	 Ordinary	Capital	Total
2019	\$ 37,405,983	\$ 640,341	\$ 38,046,324
2020	 59,852,803	2,200,822	62,053,625
Total	\$ 97,258,786	\$ 2,841,163	\$ 100,099,949

(3) There are no deposits admitted under IRC § 6603.

F. The Company is included in a consolidated federal income tax return with its parent Company, Humana Inc. The Company has a written agreement, approved by the Company's Board of Directors, which sets forth the manner in which the total combined federal income tax is allocated to each entity which is a party to the consolidation. Pursuant to this agreement, the Company has the enforceable right to be paid for any future net losses it may incur. The Company has no contingent income tax liabilities. The Company has not adjusted gross deferred tax assets due to changes in judgment about the realizability of the related deferred tax asset. The Company has no deposits under Section 6603 of the Internal Revenue Code.

# HUMANA INC. AND SUBSIDIARIES INCLUDED IN 2020 CONSOLIDATED FEDERAL INCOME TAX RETURN

## CALENDAR YEAR ENDED DECEMBER 31, 2020 AFFILIATIONS SCHEDULE

## CORPORATE NAME AND EMPLOYER IDENTIFICATION NUMBER THE ADDRESS OF EACH COMPANY IS: P. O. BOX 740026, LOUISVILLE, KY 40201

		EMPLOYER
CORP.		IDENTIFICATION
NO.	CORPORATION NAME	NUMBER
1	HUMANA INC.	61-0647538
2	154TH STREET MEDICAL PLAZA, INC.	65-0851053
3	516-526 WEST MAIN STREET CONDOMINIUM COUNCIL OF CO-OWNERS	
4	54TH STREET MEDICAL PLAZA, INC.	65-0293220
5	ARCADIAN HEALTH PLAN, INC.	20-1001348
6	CAC MEDICAL CENTER HOLDINGS, INC.	30-0117876
7	CAC-FLORIDA MEDICAL CENTERS, LLC	26-0010657
8	CARENETWORK, INC.	39-1514846
9	CAREPLUS HEALTH PLANS, INC.	59-2598550
10	CARITEN HEALTH PLAN INC.	62-1579044
11	CHA HMO, INC.	61-1279717
12	COMPBENEFITS COMPANY	59-2531815
13	COMPBENEFITS CORPORATION	04-3185995
14	COMPBENEFITS DENTAL, INC.	36-3686002
15	COMPBENEFITS DIRECT, INC.	58-2228851
16	COMPBENEFITS INSURANCE COMPANY	74-2552026
17	COMPLEX CLINICAL MANAGEMENT, INC.	45-3713941
18	CONTINUCARE CORPORATION	59-2716023
19	CONTINUCARE MEDICAL MANAGEMENT, INC.	65-0791417
20	CONVIVA HEALTH MANAGEMENT, LLC (f/k/a TRANSCEND POPULATION HEALTH MANAGEMENT, LLC)	46-5329373
21	CONVIVA HEALTH MSO OF TEXAS, INC. (f/k/a PRIMARY CARE HOLDINGS, INC.)	46-1225873
22	CONVIVA MEDICAL CENTER MANAGEMENT OF TEXAS, P.A. (f/k/a PARTNERS IN PRIMARY CARE, P.A.)	47-1161014
23	DENTAL CARE PLUS MANAGEMENT, CORP.	36-3512545
24	DENTICARE, INC.	76-0039628
25	EAGLE RX HOLDCO, INC.	47-1407967
26	EAGLE RX, INC.	47-1416614
27	EDGE HEALTH MSO, INC.	84-2214810
28	EDGE HEALTH, P.C.	84-2752906
29	EMPHESYS INSURANCE COMPANY	31-0935772
30	EMPHESYS, INC.	61-1237697
31	ENCLARA PHARMACIA, INC.	23-3068914
32	FAMILY PHYSICIANS OF WINTER PARK, INC.	59-3164234
33	FPG ACQUISITION CORP.	81-3802918
34	FPG ACQUISITION HOLDINGS CORP.	81-3819187
35	FPG HOLDING COMPANY, LLC	32-0505460
36	GUIDANTRX, INC.	39-1789830
37	HARRIS, ROTHENBERG INTERNATIONAL, INC.	27-1649291
38	HEALTH VALUE MANAGEMENT, INC.	61-1223418
39	HUMANA ACTIVE OUTLOOK, INC.	20-4835394
40	HUMANA AT HOME (DALLAS), INC.	75-2739333
41	HUMANA AT HOME (HOUSTON), INC.	76-0537878
42	HUMANA AT HOME (SAN ANTONIO), INC.	01-0766084
43	HUMANA AT HOME (TLC), INC.	75-2600512
44	HUMANA AT HOME 1, INC.	65-0274594
45	HUMANA AT HOME, INC.	13-4036798

46	HUMANA BENEFIT PLAN OF ILLINOIS, INC.	37-1326199
47	HUMANA BENEFIT PLAN OF SOUTH CAROLINA, INC.	84-3226630
48	HUMANA BENEFIT PLAN OF TEXAS, INC.	75-2043865
49	HUMANA DENTAL COMPANY	59-1843760
50	HUMANA DIGITAL HEALTH AND ANALYTICS PLATFORM SERVICES,	80-0072760
	INC.	
51	HUMANA DIRECT CONTRACTING ENTITY, INC.	85-3099097
52	HUMANA EAP AND WORK-LIFE SERVICES OF CALIFORNIA, INC.	46-4912173
53	HUMANA EMPLOYERS HEALTH PLAN OF GEORGIA, INC.	58-2209549
54	HUMANA GOVERNMENT BUSINESS, INC.	61-1241225
55	HUMANA HEALTH BENEFIT PLAN OF LOUISIANA, INC.	72-1279235
56	HUMANA HEALTH COMPANY OF NEW YORK, INC.	26-2800286
57	HUMANA HEALTH INSURANCE COMPANY OF FLORIDA, INC.	61-1041514
58	· · · · · · · · · · · · · · · · · · ·	26-3473328
	HUMANA HEALTH PLAN OF CALIFORNIA, INC.	
59	HUMANA HEALTH PLAN OF OHIO, INC.	31-1154200
60	HUMANA HEALTH PLAN OF TEXAS, INC.	61-0994632
61	HUMANA HEALTH PLAN, INC.	61-1013183
62	HUMANA HEALTHCARE RESEARCH, INC.	42-1575099
63	HUMANA HOME ADVANTAGE (TX), P.A.	81-0789608
64	HUMANA INNOVATION ENTERPRISES, INC.	61-1343791
65	HUMANA INSURANCE COMPANY	39-1263473
66	HUMANA INSURANCE COMPANY OF KENTUCKY	61-1311685
67	HUMANA INSURANCE COMPANY OF NEW YORK	20-2888723
68	HUMANA MARKETPOINT, INC.	61-1343508
69	HUMANA MEDICAL PLAN OF MICHIGAN, INC.	27-3991410
70	HUMANA MEDICAL PLAN OF PENNSYLVANIA, INC.	27-4460531
71	HUMANA MEDICAL PLAN OF UTAH, INC.	20-8411422
72	HUMANA MEDICAL PLAN, INC.	61-1103898
73	HUMANA PHARMACY SOLUTIONS, INC.	45-2254346
74	HUMANA PHARMACY, INC.	61-1316926
75	HUMANA REAL ESTATE COMPANY	20-1724127
76	HUMANA REGIONAL HEALTH PLAN, INC.	20-2036444
77	HUMANA VETERANS HEALTHCARE SERVICES, INC.	20-8418853
78	HUMANA WISCONSIN HEALTH ORGANIZATION INSURANCE	39-1525003
79	CORPORATION HUMANADENTAL INSURANCE COMPANY	39-0714280
80	HUMANADENTAL, INC.	61-1364005
81	HUMCO, INC.	61-1239538
82	HUM-e-FL, INC.	61-1383567
83	MANAGED CARE INDEMNITY, INC.	61-1232669
84	MEDICAL CARE CONSORTIUM INCORPORATED OF TEXAS	27-4379634
85	METCARE OF FLORIDA, INC.	65-0879131
86	METROPOLITAN HEALTH NETWORKS, INC.	65-0635748
87	PARTNERS IN INTEGRATED CARE, INC.	47-2905609
88	PARTNERS IN PRIMARY CARE (GA), P.C.	83-2624178
89	PARTNERS IN PRIMARY CARE (KS), P.A.	30-1236218
90	PARTNERS IN PRIMARY CARE (KS), P.C.	85-0733589
91	PARTNERS IN PRIMARY CARE (MO), P.C.	85-3676937
92	PARTNERS IN PRIMARY CARE (NC), P.C.	82-1926920
93	PARTNERS IN PRIMARY CARE (SC), P.C.	85-3577914
94	PBM HOLDING COMPANY	61-1340806
95	PBM PLUS MAIL SERVICE PHARMACY, LLC	20-2373204
96	PHP COMPANIES, INC.	62-1552091
97	PREFERRED HEALTH PARTNERSHIP, INC.	62-1250945
98	PRIMARY CARE MANAGEMENT, INC.	85-0858631
99	ROHC, LLC	75-2844854
100	SENIORBRIDGE FAMILY COMPANIES (FL), INC.	65-1096853
101	SENIORBRIDGE FAMILY COMPANIES (NY), INC.	36-4484443
102	TEXAS DENTAL PLANS, INC.	74-2352809
103	THE DENTAL CONCERN, INC.	52-1157181
104	TRANSCEND COMMUNITY PHYSICIAN NETWORK (AR), P.A.	47-2770181
105	TRANSCEND COMMUNITY PHYSICIAN NETWORK (KS), P.A.	47-2111323
106	TRANSCEND COMMUNITY PHYSICIAN NETWORK, P.C.	47-2750105

G. The Company does not have any tax loss contingencies for which it is reasonably possible that the total liability will significantly increase within twelve months of the reporting date.

# NOTES TO THE FINANCIAL STATEMENTS

#### 10. Information Concerning Parent, Subsidiaries and Affiliates

A.-B. The Company has several management contracts with Humana Inc. and other related parties whereby the Company is provided with medical and executive management, information systems, claims processing, billing and enrollment, and telemarketing and other services as required by the Company. Management fees charged to operations for the years ended December 31, 2020 and 2019 were \$554,467,058 and \$423,633,092, respectively. As a part of this agreement, Humana Inc. makes cash disbursements on behalf of the Company which includes, but is not limited to, medical related items, general and administrative expenses, commissions and payroll. The Company continues to be primarily liable for any outstanding payments made on behalf of the Company, should Humana Inc. not be able to fulfill its obligations.

In the ordinary course of business, the Company also directly contracts with related parties to provide services that are routine in nature to its members. The administrative services, access fees, and cost of care services provided are determined within each individual agreement. The following table identifies the amount for the administrative services, access fees, and cost of care services provided by related parties for the years ended December 31, 2020 and 2019, which meet the disclosure requirements pursuant to SSAP No. 25, *Affiliate and Other Related Parties* (SSAP No. 25):

	<u>2020</u>		<u>2019</u>
SeniorBridge and Humana At Home	\$ 44,436,372	\$	36,915,458
Transcend Population Health Management	(230,867)		72,227,676
Primary Care Holdings II, LLC	36,260,456		45,252,228
Total	\$ 80,465,961	\$	154,395,362

In addition to the related parties above, the Company also has a contracted relationship with Humana Pharmacy Solutions, Inc. (HPS). HPS is responsible for designing pharmacy benefits, including defining member co-share responsibilities, determining formulary listings, contracting with retail pharmacies, confirming member eligibility, reviewing drug utilization, and processing claims for Humana entities. HPS has various contracts with pharmacy manufacturers to provide the Company with purchase discounts and volume rebates on certain prescription drugs utilized by its members. The Company has an agreement with HPS to collect pharmacy rebates on its behalf and remit them to the Company on a monthly basis. The Company had \$1,504,533,053 and \$1,125,459,316 of administrative service and prescription costs in 2020 and 2019, respectively, with HPS. The prescription costs included in fees paid to HPS are gross of the pharmacy rebates that the Company receives, see Footnote 28, and also includes payments for Medicare Part D claims that CMS reimburses the Company for through the Coverage Gap, Low Income and Reinsurance subsidies.

Included in the payments to HPS are also costs incurred from Humana Pharmacy, Inc. Humana Pharmacy, Inc. provides covered members with prescription services through use of the mail order as well as brick and mortar locations. These services are limited to maintenance medication prescription drug and allied services and supplies normally provided to the general public in the ordinary course of pharmacy business. The Company had \$504,044,249 and \$371,863,254 of prescription costs in 2020 and 2019, respectively, with Humana Pharmacy, Inc.

No dividends or returns of capital were paid by the Company as of December 31, 2020.

The Company received a \$30,000,000 capital contribution from Humana Inc. on March 31, 2020.

C. (1) Detail of Material Related Party Transactions

Not Applicable.

(2) Detail of Material Related Party Transactions Involving Services

Not Applicable.

(3) Detail of Material Related Party Transactions Exchange of Assets and Liabilities

Not Applicable.

(4) Detail of Amounts Owed To/From a Related Party

Not Applicable.

- D. At December 31, 2020, the Company reported \$15,412,094 due to Humana Inc. Amounts due to or from parent are generally settled within 90 days.
- E. Not Applicable.
- F. Not Applicable.
- G. All outstanding shares of the Company are owned by the Parent Company.
- H. Not Applicable.
- I. Not Applicable.
- J. Not Applicable.
- K. Not Applicable.
- L. Not Applicable.
- M. All SCA Investments

# NOTES TO THE FINANCIAL STATEMENTS

Not Applicable.

N. Investment in Insurance SCA

Not Applicable.

O. SCA Loss Tracking

Not Applicable.

### 11. <u>Debt</u>

A. Debt Including Capital Notes

The Company has no debentures outstanding.

The Company has no capital notes outstanding.

The Company does not have any reverse repurchase agreements.

B. Federal Home Loan Bank (FHLB) Agreements

The Company does not have any FHLB agreements.

## 12. <u>Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement</u> <u>Benefit Plans</u>

A.-D. Defined Benefit Plans

Not Applicable.

E. Defined Contribution Plans

Not Applicable.

F. Multiemployer Plans

Not Applicable.

G. Consolidated/Holding Company Plans

The Company employees are eligible to participate in the Humana Retirement and Savings Plan ("the Plan"), a defined contribution plan, sponsored by Humana Inc. The Plan maintains two accounts, the Savings Account and the Retirement Account.

Humana Inc.'s total contributions paid to the Savings and Retirement accounts of the Humana Retirement Savings Plan were \$233,856,665 and \$219,268,247 for the years ended December 31, 2020 and 2019, respectively. Of these contributions, the Company contributed \$8,011 and \$22,091 during 2020 and 2019, respectively. As of December 31, 2020 and 2019, the fair market value of the Humana Retirement Savings Plan's assets was \$6,280,051,531 and \$5,344,599,370, respectively.

H. Postemployment Benefits and Compensated Absences

Not Applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not Applicable.

## 13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

- A. The Company has \$16.667 par value common stock with 60,000 shares authorized and 60,000 shares issued and 60,000 outstanding. All shares are common stock shares.
- B. The Company has no preferred stock outstanding.
- C.-E. Dividends and returns of capital to shareholders are noncumulative and are paid as determined by the Board of Directors. In accordance with the Office statutes, the maximum amount which can be paid by the Company to shareholders without prior approval by the Office is the lesser of 10% of total surplus, or the greater of net operating gain for the calendar year preceding the dividend or for the 3 calendar years preceding the dividend less dividends paid for the most recent 2 of those calendar years. All ordinary dividends are limited to available and accumulated surplus funds. Based on these restrictions, the Company could have paid a maximum dividend or return of capital to shareholders of approximately \$71,670,000 in 2020 without prior regulatory approval.

Within the limitations above, there are no restrictions placed on the portion of Company profits that may be paid as ordinary dividends to stockholders.

No dividends or returns of capital were paid by the Company as of December 31, 2020.

F. There were no restrictions placed on the Company's surplus, including for whom the surplus is being held.

# NOTES TO THE FINANCIAL STATEMENTS

- G. Not Applicable.
- H. Not Applicable.
- I. Changes in balances of special surplus funds from the prior year is due to the health insurance industry fee having been permanently repealed beginning calendar year 2021.
- J. The portion of unassigned funds (surplus) represented or reduced by cumulative unrealized gains and losses is \$57,176.
- K. Not Applicable.
- L. Not Applicable.
- M. Not Applicable.
- 14. Liabilities, Contingencies and Assessments
  - A. Contingent Commitments

Not Applicable.

B. Assessments

Not Applicable.

C. Gain Contingencies

Not Applicable.

D. Claims related extra contractual obligation and bad faith losses stemming from lawsuits

Not Applicable.

E. Joint and Several Liabilities

Not Applicable.

F. All Other Contingencies

During the ordinary course of business, the Company is subject to pending and threatened legal actions. Management of the Company does not believe that any of these actions will have a material adverse effect on the Company's surplus, results of operations or cash flows. However, the likelihood or outcome of current or future legal proceedings cannot be accurately predicted, and they could adversely affect the Company's surplus, results of operations and cash flows.

The Company is not aware of any other material contingent liabilities as of December 31, 2020.

15. Leases

Not Applicable.

16. <u>Information about Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk</u>

The Company has no investment in Financial Instruments with Off-Balance Sheet Risk or Concentrations of Credit Risk.

- 17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities
  - A. Transfers of Receivables Reported as Sales

Not Applicable.

B. Transfer and Servicing of Financial Assets

Not Applicable.

C. Wash Sales

Not Applicable.

- 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans
  - A. ASO Plans

Not Applicable.

B. ASC Plans

Not Applicable.

- C. Medicare or Other Similarly Structured Cost Based Reimbursement Contract
  - (1) The Company records no revenue explicitly attributable to the cost share and reinsurance components of its Medicare or other similarly structured cost based reimbursement contracts.
  - (2) As of December 31, 2020, the Company has recorded a receivable from CMS of \$33,442,902 related to the cost share and reinsurance components of administered Medicare products. The Company does not have any receivables greater than 10% of the Company's accounts receivable from uninsured accident and health plans or \$10,000.
  - (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare or other similarly structured cost based reinbursement contracts, the Company has recorded no allowances and reserves for adjustment of recorded revenues and receivables.
  - (4) The Company has made no adjustment to revenue resulting from audit of receivables related to revenues recorded in the prior period.

#### 19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

Not Applicable.

#### 20. Fair Value Measurements

A. (1) The fair value of financial assets at December 31, 2020 were as follows:

						Net Asset		
	Lev	vel 1	Level 2	]	Level 3	Value (NAV)	Total	
a. Assets at fair value								
Bonds								
U.S. governments	\$	-	\$ -	\$	- \$	-	\$	-
Tax-exempt municipal		-	-		-	-		-
Residential mortgage-backed		-	-		-	-		-
Corporate debt securities		-	3,059,328		-	-		3,059,328
Total bonds		-	3,059,328		-	-		3,059,328
Total assets at fair value/NAV	\$	-	\$ 3,059,328	\$	- \$	-	\$	3,059,328
b. Liabilities at fair value	\$	-	\$ -	\$	- \$	-	\$	-
Total liabilities at fair value	\$	-	\$ -	\$	- \$	-	\$	-

The Company reports transfers between Level 1 and Level 2 of the fair value hierarchy levels at the end of the reporting period. There were no transfers between Level 1 and Level 2 of the fair value hierarchy between December 31, 2019 and December 31, 2020.

(2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

Not Applicable.

- (3) The Company reports transfers into or out of Level 3 of the fair value hierarchy levels at the end of the reporting period. There were no transfers into or out of Level 3 of the fair value hierarchy levels between December 31, 2019 and December 31, 2020.
- (4) Fair value of actively traded debt securities are based on quoted market prices. Fair value of other debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates generally using a market valuation approach, or, less frequently, an income valuation approach and are generally classified as Level 2. The Company generally obtains one quoted price for each security from a third party pricing service. These prices are generally derived from recently reported trades for identical or similar securities, including adjustments through the reporting date based upon observable market information. When quoted prices are not available, the third party pricing service may use quoted market prices of comparable securities or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include benchmark yields, reported trades, credit spreads, broker quotes, default rates and prepayment speeds. The Company is responsible for the determination of fair value and as such, the Company performs analysis on the prices received from the third party pricing service to determine whether the prices are reasonable estimates of fair value. The Company's analysis includes a review of monthly price fluctuations as well as a quarterly comparison of the prices received from the pricing service to prices reported by the Company's third party investment advisor. Based on the Company's internal price verification procedures and review of fair value methodology documentation provided by the third party pricing service, there were no material adjustments to the prices obtained from the third party pricing service during the year ended December 31, 2020.
- (5) Derivative Fair Values

Not Applicable.

B. Other Fair Value Disclosures

Not Applicable.

C. Fair Values for All Financial Instruments by Levels 1, 2 and 3

Type of Financial									Net Asset	Not Practicable
Instrument	Aggr	egate Fair Value	Ad	mitted Assets	Level 1	Level 2	Le	vel 3	Value (NAV)	(Carrying Value)
Bonds, short-term										
investments and										
cash equivalents	\$	1,230,979,412	\$	1,190,644,735	\$ 198,659,038	\$ 1,032,320,374	\$	-	\$ -	\$ -

D. Financial Instruments for which Not Practicable to Estimate Fair Values

Not Applicable.

## 21. Other Items

A. Extraordinary Items

The emergence and spread of the novel coronavirus, or COVID-19, has impacted the Company's business. Beginning in the second half of March 2020, the implementation of stay-at-home and physical distancing orders and other restrictions on movement and economic activity resulted in the temporary deferral of non-essential care and significant reduction in hospital admissions and overall healthcare system utilization during April 2020. Non-COVID utilization then began to increase during May and June 2020 and continued to rebound throughout the third quarter and early in the fourth quarter of 2020. Then, in the latter half of November and accelerating throughout the month of December, the Company experienced a significant increase in COVID-19 admissions in nearly all of the markets in which it operates across the Company's lines of business resulting in higher COVID-19 treatment and testing costs.

B. Troubled Debt Restructuring: Debtors

Not Applicable.

C. Other Disclosures and Unusual Items

Not Applicable.

D. Business Interruption Insurance Recoveries

Not Applicable.

E. State Transferable and Non-transferable Tax Credits

Not Applicable.

- F. Subprime Mortgage Related Risk Exposure
  - (1) The Company consults with its external investment managers to assess its subprime mortgage related risk exposure. Certain characteristics are utilized to determine if a mortgage-backed security has subprime exposure. The main characteristics reviewed when determining this are the collateral and structure of the security, the loan purpose, loan documentation, occupancy, geographical location, loan size and type. Subprime mortgage borrowers typically have lower credit scores, lower loan balances and higher loan-to-values than other conforming loans. Management's practices include reviewing quantitative and qualitative credit models that analyze loan-level collateral composition, historical underwriter performance trends, the impact of macroeconomic factors, and issuer risks; as well as reviewing the estimation of security cash flows and monthly model calibrations.
  - (2) Direct exposure through investments in sub-prime mortgage loans.

The Company has no direct exposure through investment to sub-prime mortgage loans.

- (3) Direct exposure through other investments:
  - a. Residential mortgage backed securities No substantial exposure noted.
  - b. Commercial mortgage backed securities No substantial exposure noted.
  - c. Collateralized debt obligations No substantial exposure noted.
  - d. Structured securities No substantial exposure noted.
  - e. Equity investment in SCAs No substantial exposure noted.
  - f. Other assets No substantial exposure noted.
  - g. Total No substantial exposure noted.
- (4) Underwriting exposure to sub-prime mortgage risk through Mortgage Guaranty coverage, Financial Guaranty coverage, Directors and Officers liability coverage, or Errors and Omissions liability coverage.

The Company does not have sub-prime mortgage risk.

Classification of mortgage related securities is primarily based on information from outside data services, including rating agency actions. When considering our exposure, the Company evaluated the percentage of full documentation loans, percent of owner occupied properties, FICO scores, average margin for ARM loans, percent of loans with prepayment penalties, the existence of non-traditional underwriting standards, among other factors.

G. Retained Assets

Not Applicable.

H. Insurance Linked Securities

#### Not Applicable.

#### 22. Events Subsequent

On January 1, 2020 the Company was subject to the annual fee under Section 9010 of the Federal Affordable Care Act (ACA). The Consolidated Appropriations Act enacted on December 18, 2015, included a one-time one year suspension in 2017 of the health insurer fee. The Continuing Resolution bill, H.R. 195, enacted on January 22, 2018, included a one year suspension in 2019 of the health insurer fee, but the fee has resumed for calendar year 2020. A segregation was recorded within special surplus for the annual health insurance industry fee related to the 2019 data year for the 2020 fee. This annual fee was allocated to individual health insurers based on the ratio of the amount of the entity's net premiums written during the preceding calendar year to the amount of health insurance for any U.S. health risk that was written during the preceding calendar year. The 2020 fee was paid September 30, 2020. The impact of the annual health insurance industry fee on the Company's operations as of December 31, 2020 and 2019 were as follows:

		 Current Year	Prior Year
A.	Did the reporting entity write accident and health insurance premium that is subject to Section 9010 of the federal Affordable Care Act (YES/NO)?	No	
B.	ACA fee assessment payable for the upcoming year	\$ -	\$ 86,545,504
C.	ACA fee assessment paid	\$ 91,320,689	\$ -
D.	Premiums written subject to ACA 9010 assessment	\$ -	\$ 4,353,829,769
E.	Total Adjusted Capital before surplus adjustment (Five-Year Historical Line 14)	\$ 879,045,229	\$ 630,222,934
F.	Total Adjusted Capital after surplus adjustment (Five-Year Historical Line 14 minus 22B above)	\$ 879,045,229	\$ 630,222,934
G.	Authorized Control Level (Five-Year Historical Line 15)	\$ 137,325,207	\$ 108,214,412
H.	Would reporting the ACA assessment as of December 31, 2020, have triggered an RBC action level (YES/NO)	No	

The further consolidated Appropriations Act 2020, enacted on December 20, 2019, permanently repealed the health insurance industry fee for calendar years 2021 and thereafter.

The Company is not aware of any events or transactions occurring subsequent to the close of the books for this statement which may have a material effect on its financial condition. Subsequent events have been considered through February 25, 2021 for the Statutory Statement issued on February 25, 2021.

#### 23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers, listed in Schedule S as non-affiliated, owned in excess of 10.0 percent or controlled, either directly or indirectly, by the company or by any representative, officer, trustee, or director of the company?

Yes ( ) No (X)

(2) Have any policies issued by the company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10.0 percent or controlled directly or indirectly by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes ( ) No (X)

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the company may consider the current or anticipated experience of the business

# NOTES TO THE FINANCIAL STATEMENTS

reinsured in making this estimate. \$0

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the company as of the effective date of the agreement?

Yes ( ) No ( X )

B. Uncollectible Reinsurance

Not Applicable.

C. Commutation of Ceded Reinsurance

Not Applicable.

D. Certified Reinsurer Rating Downgraded or Status Subject to Revocation

Not Applicable.

- 24. Retrospectively Rated Contracts and Contracts Subject to Redetermination
  - A. The Company estimates accrued retrospective premium adjustments for its Medicare business through a mathematical approach using an algorithm based upon settlement procedures defined by contracts with CMS.
  - B. The Company records accrued retrospective premium as an adjustment to earned premiums.
  - C. The amount of net premiums written by the Company at December 31, 2020 that are subject to retrospective rating features was \$5,513,801,635, or 100.00% of the total net premiums written. No other net premiums written by the Company are subject to retrospective rating features.
  - D. Medical loss ratio rebates required pursuant to the Public Health Service Act

Not Applicable.

E. Risk Sharing Provisions of the Affordable Care Act

Not Applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

Benefits and loss adjustment expenses payable, net of health care receivables, as of December 31, 2019 were \$363,487,554. As of December 31, 2020, \$357,364,302 has been paid for incurred claims and claim adjustment expenses attributable to insured events of prior years. Reserves remaining for prior years are now \$8,451,069 as a result of re-estimation of unpaid claims and claim adjustment expenses. Therefore, there has been a \$2,327,818 unfavorable prior-year development since December 31, 2019. The increase is generally the result of ongoing analysis of recent loss development trends. Original estimates are increased or decreased as additional information becomes known regarding individual claims. Included in this increase, the Company experienced \$2,327,818 of unfavorable prior year claim development on retrospectively rated policies. However, the business to which it relates is subject to premium adjustments.

26. Intercompany Pooling Arrangements

Not Applicable.

27. Structured Settlements

The Company has no structured settlements.

## NOTES TO THE FINANCIAL STATEMENTS

#### 28. Health Care Receivables

#### A. Pharmaceutical Rebate Receivables

	Quarter	timate Pharmacy pates as Reported on Financial Statements	Ph	armacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Receiv to 1	ual Rebates /ed Within 91 80 Days of Billing	Reco than	ual Rebates eived More n 181 Days er Billing
12	2/31/2020	\$ 89,378,981	\$	89,378,981	\$ -	\$	-	\$	-
ç	9/30/2020	120,547,639		120,547,639	119,638,771		-		-
(	5/30/2020	134,630,331		134,630,331	133,427,752		1,119,304		-
3	3/31/2020	98,641,596		98,641,596	96,236,730		2,404,866		-
12	2/31/2019	73,283,351		73,283,351	72,896,071		-		-
ç	9/30/2019	81,082,048		81,082,048	80,521,374		168,994		391,680
(	5/30/2019	119,518,755		119,518,755	118,016,591		388,230		1,113,934
3	3/31/2019	78,040,458		78,040,458	77,296,766		-		743,692
12	2/31/2018	56,761,098		56,761,098	56,106,624		273,710		160,334
ç	9/30/2018	68,353,073		68,353,073	68,123,613		229,460		-
6	5/30/2018	82,118,478		82,118,478	81,769,886		348,592		-
3	3/31/2018	50,657,583		50,657,583	50,657,583		-		-

### B. Risk Sharing Receivables

Not Applicable.

### 29. Participating Policies

The Company has no participating policies.

#### 30. Premium Deficiency Reserves

Not Applicable.

#### 31. Anticipated Salvage and Subrogation

Not Applicable.

## **GENERAL INTERROGATORIES**

# PART 1 - COMMON INTERROGATORIES

### GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System is an insurer? If yes, complete Schedule Y, Parts 1, 1A and 2		
1.2	If yes, did the reporting entity register and file with its domiciliary State Insu such regulatory official of the state of domicile of the principal insurer in the providing disclosure substantially similar to the standards adopted by the N its Model Insurance Holding Company System Regulatory Act and model re subject to standards and disclosure requirements substantially similar to the	Holding Company System, a registration statement ational Association of Insurance Commissioners (NAIC) in equilations pertaining thereto, or is the reporting entity	Yes [ X ] No [ ] N/A [ ]
1.3	State Regulating?		Washington
1.4	Is the reporting entity publicly traded or a member of a publicly traded group	o?	Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issue	ed by the SEC for the entity/group.	0000049071
2.1	Has any change been made during the year of this statement in the charter reporting entity?		
2.2	If yes, date of change:		
3.1	State as of what date the latest financial examination of the reporting entity	was made or is being made.	12/31/2020
3.2	State the as of date that the latest financial examination report became ava entity. This date should be the date of the examined balance sheet and not		03/31/2019
3.3	State as of what date the latest financial examination report became availa domicile or the reporting entity. This is the release date or completion date examination (balance sheet date).	of the examination report and not the date of the	12/12/2019
3.4	By what department or departments? Washington Department of Insurance/California Department of Managed H	lealthcare	
3.5	Have all financial statement adjustments within the latest financial examina statement filed with Departments?		Yes [X] No [] N/A []
3.6	Have all of the recommendations within the latest financial examination rep	ort been complied with?	Yes [X] No [] N/A []
4.1 4.2		of the reporting entity), receive credit or commissions for or of sured on direct premiums) of: new business? 	control Yes [ ] No [ X ] Yes [ ] No [ X ]
	premiums) of:	new business?	Yes [ ] No [ X ]
	4.22 renewals	s?	Yes [ ] No [ X ]
5.1	Has the reporting entity been a party to a merger or consolidation during the If yes, complete and file the merger history data file with the NAIC.	e period covered by this statement?	Yes [ ] No [ X ]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of do ceased to exist as a result of the merger or consolidation.		as
	1 Name of Entity	2 3 NAIC Company Code State of Domicile	
6.1	Has the reporting entity had any Certificates of Authority, licenses or registr revoked by any governmental entity during the reporting period?		
6.2	If yes, give full information:		
7.1	Does any foreign (non-United States) person or entity directly or indirectly or	control 10% or more of the reporting entity?	Yes [ ] No [X]
7.2	If yes, 7.21 State the percentage of foreign control; 7.22 State the nationality(s) of the foreign person(s) or entity(s) or if the ent attorney-in-fact; and identify the type of entity(s) (e.g., individual, corporation)	ity is a mutual or reciprocal, the nationality of its manager or	
	1 Nationality	2 Type of Entity	

# **GENERAL INTERROGATORIES**

8.1 8.2	Is the company a subsidiary of a bank holding company regulated by the Federal Resolf response to 8.1 is yes, please identify the name of the bank holding company. Not Applicable.					Yes [	]	No [	X ]
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities firms? If response to 8.3 is yes, please provide below the names and location (city and state regulatory services agency [i.e. the Federal Reserve Board (FRB), the Office of the Co Insurance Corporation (FDIC) and the Securities Exchange Commission (SEC)] and in	of the main office) of any affiliates ro omptroller of the Currency (OCC), th	egulated l ie Federa	oy a fec I Depos	eral	Yes [	]	No [	X ]
	1 Affiliate Name L	2 ocation (City, State)	3 FRB	4 OCC	5 FDIC	6 SEC			
10.2 10.3 10.4 10.5	allowed for in Section 18A of the Model Regulation, or substantially similar state law o If the response to 10.3 is yes, provide information related to this exemption: Has the reporting entity established an Audit Committee in compliance with the domic If the response to 10.5 is no or n/a, please explain What is the name, address and affiliation (officer/employee of the reporting entity or ad firm) of the individual providing the statement of actuarial opinion/certification? Drew Besendorf, Appointed Actuary, 500 West Main Street, Louisville, KY 40202 Does the reporting entity own any securities of a real estate holding company or other 12.11 Name of real estate holding company or	ky 40202-4264 vided by the certified independent p lation (Model Audit Rule), or substa Annual Financial Reporting Model I r regulation? iliary state insurance laws? ctuary/consultant associated with ar wise hold real estate indirectly?	ublic accontrally sim	ountant nilar sta n as Y	te  es [ X  ting	Yes [ 0	] ]	No [ N/A No [	X ] X ]
12.2 13.	12.13 Total book/adjusted carrying v If, yes provide explanation: FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIES ONLY:	alue				\$			0
13.1	What changes have been made during the year in the United States manager or the U Not Applicable.								
13.2	Does this statement contain all business transacted for the reporting entity through its	United States Branch on risks when	ever loca	ted?		Yes [	]	No [	]
13.3	Have there been any changes made to any of the trust indentures during the year?					Yes [	]	No [	]
13.4						] No [	]	N/A	[X]
14.1	<ul> <li>similar functions) of the reporting entity subject to a code of ethics, which includes the a. Honest and ethical conduct, including the ethical handling of actual or apparent con relationships;</li> <li>b. Full, fair, accurate, timely and understandable disclosure in the periodic reports required. Compliance with applicable governmental laws, rules and regulations;</li> <li>d. The prompt internal reporting of violations to an appropriate person or persons iden e. Accountability for adherence to the code.</li> </ul>	following standards? flicts of interest between personal a uired to be filed by the reporting enti	nd profes			Yes [ X	[]	No [	]
14.11	If the response to 14.1 is No, please explain:								
	Has the code of ethics for senior managers been amended? If the response to 14.2 is yes, provide information related to amendment(s).					Yes [ X	1	No (	]
	It the response to 14.2 is yes, provide information related to amendment(s). Ethics Every Day was amended in June 2020 to update content based on operational necessary and perform general document maintenance. Have any provisions of the code of ethics been waived for any of the specified officers					Veo [	1	No. T	V I
	If the response to 14.3 is yes, provide the nature of any waiver(s).					Yes [	1	INU [	v ]

# **GENERAL INTERROGATORIES**

	If the response to 15		on (ABA) Routing Number and the name of the issuing or confirming e Letter of Credit is triggered.	Yes [ ] No	-
	1	2	3	4	
	American Bankers Association	-			
	(ABA) Routing			<b>A</b>	
	Number	Issuing or Confirming Bank Name	Circumstances That Can Trigger the Letter of Credit	Amount	
			D OF DIRECTORS		
			upon either by the board of directors or a subordinate committee	Yes [X] No	, r
			eedings of its board of directors and all subordinate committees		-
					)[
			pard of directors or trustees of any material interest or affiliation on the nat is in conflict with the official duties of such person?		) [
			FINANCIAL		
	Has this statement b	een prepared using a basis of accounting other that	in Statutory Accounting Principles (e.g., Generally Accepted		
	Accounting Principle	s)?	xclusive of policy loans): 20.11 To directors or other officers	Yes [ ] No	) [ )
		during the year (inclusive of Separate Accoullits, e)	20.11 To directors or other officers		
			20.13 Trustees, supreme or grand		
	T. (.)		(Fraternal Only)	\$	
	policy loans):	ns outstanding at the end of year (inclusive of Separa	ate Accounts, exclusive of 20.21 To directors or other officers	\$	
			20.22 To stockholders not officers		
			20.23 Trustees, supreme or grand	•	
	Were any assets rer	ported in this statement subject to a contractual oblic	(Fraternal Only) gation to transfer to another party without the liability for such	ֆ	
	obligation being repo	orted in the statement?			
	If yes, state the amo	unt thereof at December 31 of the current year:	21.21 Rented from others		
			21.22 Borrowed from others 21.23 Leased from others		
			21.23 Cleased from others		
	Does this statement	include payments for assessments as described in	the Annual Statement Instructions other than guaranty fund or		
	guaranty association If answer is yes:	assessments?	22.21 Amount paid as losses or risk adjustme		
			22.22 Amount paid as losses of hisk adjustine 22.22 Amount paid as expenses	-	
			22.23 Other amounts paid		
			ies or affiliates on Page 2 of this statement?		•
	If yes, indicate any a	mounts receivable from parent included in the Page	e 2 amount:	\$	
			NVESTMENT		
			-		
1			current year, over which the reporting entity has exclusive control, in ecurities lending programs addressed in 24.03).	Yes [X] No	) [
_					-
2	-	omplete information relating thereto			
5	For securities lendin	g programs, provide a description of the program in	ncluding value for collateral and amount of loaned securities, and		
			preference Note 17 where this information is also provided)		
	For the reporting ent	ity's securities lending program, report amount of co	ollateral for conforming programs as outlined in the Risk-Based Capita	al e	
ŀ			ollateral for other programs.		
1	For the reporting ent	,		······	
5					
	Does your securities	lending program require 102% (domestic securities t?	s) and 105% (foreign securities) from the counterparty at the Yes	[ ] No [ ] N	N/A
;	Does your securities outset of the contract	xt?	s) and 105% (foreign securities) from the counterparty at the Yes ne counterparty falls below 100%?		

# **GENERAL INTERROGATORIES**

24.09 For the reporting entity's securities lending program state the amount of the following as of December 31 of the current year:

	24.091 Total fair value of reinvested collateral assets repo	rted on Schedule DL, Parts 1 and 2.	\$0
	24.092 Total book adjusted/carrying value of reinvested co	ollateral assets reported on Schedule DL, Parts 1 and 2	\$0
	24.093 Total payable for securities lending reported on the	e liability page.	\$0
5.1	Were any of the stocks, bonds or other assets of the reporting entity owned		
	control of the reporting entity, or has the reporting entity sold or transferred force? (Exclude securities subject to Interrogatory 21.1 and 24.03).	any assets subject to a put option contract that is currently in	Yes [ X ] No [ ]
5.2	If yes, state the amount thereof at December 31 of the current year:	25.21 Subject to repurchase agreements	\$0
		25.22 Subject to reverse repurchase agreements	\$0
		25.23 Subject to dollar repurchase agreements	\$0
		25.24 Subject to reverse dollar repurchase agreements	\$0
		25.25 Placed under option agreements	\$0
		25.26 Letter stock or securities restricted as to sale - excluding FHLB Capital Stock	
		25.27 FHLB Capital Stock	
		25.28 On deposit with states	\$
		25.29 On deposit with other regulatory bodies	
		25.30 Pledged as collateral - excluding collateral pledged t an FHLB	h
		25.31 Pledged as collateral to FHLB - including assets backing funding agreements	
		25.32 Other	

#### 25.3 For category (25.26) provide the following:

25.

25.

	1 Nature of Restriction	2 Description	Am	3 iount	
26.1	Does the reporting entity have any hedging transactions reported on Sc	chedule DB?	Yes [	] No [	X ]
26.2	If yes, has a comprehensive description of the hedging program been n If no, attach a description with this statement.	nade available to the domiciliary state? Yes [	] No [	] N/A	[X
LINES 2	6.3 through 26.5: FOR LIFE/FRATERNAL REPORTING ENTITIES ON	LY:			
26.3	Does the reporting entity utilize derivatives to hedge variable annuity gu	uarantees subject to fluctuations as a result of interest rate sensitivity?	Yes [	] No [	]
26.4	26.42 Per	ecial accounting provision of SSAP No. 108 mitted accounting practice er accounting guidance			] ] ]
26.5	<ul> <li>reserves and provides the impact of the hedging strategy within</li> <li>Financial Officer Certification has been obtained which indicated</li> </ul>	miciliary state. is consistent with the requirements of VM-21. he hedging strategy is incorporated within the establishment of VM-21	Yes [	] No [	]
27.1	Were any preferred stocks or bonds owned as of December 31 of the c issuer, convertible into equity?	current year mandatorily convertible into equity, or, at the option of the	Yes [	] No [	X ]
27.2	If yes, state the amount thereof at December 31 of the current year		\$		
28.	Excluding items in Schedule E - Part 3 - Special Deposits, real estate, r offices, vaults or safety deposit boxes, were all stocks, bonds and other custodial agreement with a qualified bank or trust company in accordan Outsourcing of Critical Functions, Custodial or Safekeeping Agreement	r securities, owned throughout the current year held pursuant to a	Yes [ ]	X ] No [	]
28.01	For agreements that comply with the requirements of the NAIC Financia	al Condition Examiners Handbook, complete the following:			

28.01 For agreements that comply with the requirements of the NAIC Financial Condition Examiners Handbook, complete the following:

1	2
Name of Custodian(s)	Custodian's Address
	4 Metro Tech Center, 6th Floor, Mail Code: NY1-C512, Brooklyn, NY 11245, Attn: Charline
JP Morgan Chase	Ottley
•	

# **GENERAL INTERROGATORIES**

28.02 For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)
		· · · ·

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason
		5	

Yes [ ] No [ X ]

28.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1	2
Name of Firm or Individual	Affiliation
BLACKROCK FINANCIAL MANAGEMENT, INC	U
W. Mark Preston	I

# 28.06 For those firms or individuals listed in the table for 28.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Managemen
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
107105	BLACKROCK FINANCIAL MANAGEMENT, INC	549300LVXY1VJKE13M84	The SEC	DS

29.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP #	Name of Mutual Fund	Carrying Value
29.2999 - Total		0

29.3 For each mutual fund listed in the table above, complete the following schedule:

	1	2	3	4
			Amount of Mutual	
			Fund's Book/Adjusted	
			Carrying Value	
		Name of Significant Holding of the	Attributable to the	Date of
Na	ame of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

# **GENERAL INTERROGATORIES**

30. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
30.1 Bonds	1, 190, 563, 300	1,230,898,621	40,335,321
30.2 Preferred stocks	0	0	0
30.3 Totals	1,190,563,300	1,230,898,621	40,335,321

30.4 Describe the sources or methods utilized in determining the fair values:

30.4	Describe the sources of methods utilized in determining the fair values.				
	Fair value of actively traded debt and equity securities are based on quoted market prices. Fair value of inactively traded debt securities are based on quoted market prices of identical or similar securities or based on observable inputs like interest rates using either a market or income valuation.				
31.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Yes [	]	No [ X	]
31.2	If the answer to 31.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Yes [	]	No [	]
31.3	If the answer to 31.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:				
	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed? If no, list exceptions:	Yes [ X	]	No [	]
33.	<ul> <li>By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security:</li> <li>a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available.</li> <li>b. Issuer or obligor is current on all contracted interest and principal payments.</li> <li>c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal.</li> <li>Has the reporting entity self-designated 5GI securities?</li> </ul>	Yes [	1	ΝοΓΧ	1
34.	<ul> <li>By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security:</li> <li>a. The security was purchased prior to January 1, 2018.</li> <li>b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.</li> <li>c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators.</li> <li>d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO.</li> <li>Has the reporting entity self-designated PLGI securities?</li> </ul>	Yes [			
35.	<ul> <li>By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: <ul> <li>a. The shares were purchased prior to January 1, 2019.</li> <li>b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security.</li> <li>c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019.</li> <li>d. The fund only or predominantly holds bonds in its portfolio.</li> <li>e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO.</li> <li>f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed.</li> </ul> </li> <li>Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?</li> </ul>	Yes [	]	No [ X	]
36.	<ul> <li>By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: <ul> <li>a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date.</li> <li>b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties.</li> <li>c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review.</li> <li>d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 36.a -</li> </ul> </li> </ul>				

# **GENERAL INTERROGATORIES**

### OTHER

37.1	Amount of payments to trade associations, service organizations and statistical or rating bureaus, if any?	\$	0
37.2	List the name of the organization and the amount paid if any such payment represented 25% or more of the total paymer service organizations and statistical or rating bureaus during the period covered by this statement.	ts to trade associations,	
		2 nt Paid	
38.1	Amount of payments for legal expenses, if any?	\$	6,049
38.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payments for leg during the period covered by this statement.	gal expenses	
		2	
	Name         Amou           FALKENBERG IVES LLP	nt Paid 6,049	
39.1	Amount of payments for expenditures in connection with matters before legislative bodies, officers or departments of gov	ernment, if any?\$	0
39.2	List the name of the firm and the amount paid if any such payment represented 25% or more of the total payment expend connection with matters before legislative bodies, officers or departments of government during the period covered by thi		

1	2
Name	Amount Paid

# **GENERAL INTERROGATORIES**

### PART 2 - HEALTH INTERROGATORIES

1.1	Does the reporting entity have any direct Medicare Supplement Insurance in force?			
1.2 1.3	If yes, indicate premium earned on U.S. business only What portion of Item (1.2) is not reported on the Medicare Supplement Insurance E 1.31 Reason for excluding			
1.4	Indicate amount of earned premium attributable to Canadian and/or Other Alien not	tincluded in Item (1.2) above	\$	0
1.5	Indicate total incurred claims on all Medicare Supplement Insurance.			
1.6	Individual policies:	Most current three years:	.Ψ	
1.0		1.61 Total premium earned	\$	0
		1.62 Total incurred claims	.Ψ ¢	ەە 0
		1.63 Number of covered lives		
				0
		All years prior to most current three years:	۴	0
		1.64 Total premium earned		
		1.65 Total incurred claims 1.66 Number of covered lives		
		1.00 Number of covered lives		0
1.7	Group policies:	Most current three years:		
		1.71 Total premium earned	\$	0
		1.72 Total incurred claims		
		1.73 Number of covered lives		
		All years prior to most current three years:		0
		1.74 Total premium earned	¢	^
		1.74 Total premium earned		
		1.75 Total incurred claims		
				0
2.	Health Test:			
		1 2		
		Current Year Prior Year		
	2.1 Premium Numerator			
	2.2 Premium Denominator			
	2.3 Premium Ratio (2.1/2.2)			
	2.4 Reserve Numerator			
	2.5 Reserve Denominator			
	2.6 Reserve Ratio (2.4/2.5)			
3.2	returned when, as and if the earnings of the reporting entity permits?		Yes [ ] N	IU [ X ]
4.1	Have copies of all agreements stating the period and nature of hospitals', physician dependents been filed with the appropriate regulatory agency?		Yes [X] N	lo [ ]
4.2	If not previously filed, furnish herewith a copy(ies) of such agreement(s). Do these a	agreements include additional benefits offered?	Yes [ ] N	lo [ X ]
5.1	Does the reporting entity have stop-loss reinsurance?		Yes [ ] N	lo [ X ]
5.2	If no, explain: Stop-Loss Reinsurance is not required			
5.3	Maximum retained risk (see instructions)	5.31 Comprehensive Medical		
	·	5.32 Medical Only	.\$	0
		5.33 Medicare Supplement	.\$	0
		5.34 Dental & Vision		
		5.35 Other Limited Benefit Plan		
		5.36 Other	.\$	0
6.	Describe arrangement which the reporting entity may have to protect subscribers a hold harmless provisions, conversion privileges with other carriers, agreements with agreements: Provider contracts include hold harmless and continuation of benefits provisions. In company.	h providers to continue rendering services, and any other nsurer has an indemnity agreement with the parent		
7.1	Does the reporting entity set up its claim liability for provider services on a service of		Yes [X] N	lo [ ]
7.2	If no, give details			
8.	Provide the following information regarding participating providers:	8.1 Number of providers at start of reporting year .		
		8.2 Number of providers at end of reporting year	·····	196,098
<b>.</b> .			V	
9.1	Does the reporting entity have business subject to premium rate guarantees?		ĭes [X] N	IO [ ]
9.2	If yes, direct premium earned:	9.21 Business with rate guarantees between 15-36 months.	¢	428 000
5.2		9.22 Business with rate guarantees over 36 months		

# **GENERAL INTERROGATORIES**

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its p	provider contracts?	Yes [ X ]	No [	]
10.2	If yes: 1	0.21 Maximum amount payable bonuses	\$	91,212	2,103
	1	0.22 Amount actually paid for year bonuses	\$		3,537
	1	0.23 Maximum amount payable withholds	\$		0
	1	0.24 Amount actually paid for year withholds	þ		0
11.1	Is the reporting entity organized as:	11.12 A Medical Group/Staff Model, 11.13 An Individual Practice Association (IPA), or, . 11.14 A Mixed Model (combination of above)?	Yes [ ] Yes [ ] Yes [ ]		X j
11.2	Is the reporting entity subject to Statutory Minimum Capital and Surplus Requirements	?	Yes [ X ]	No [	]
11.3	If yes, show the name of the state requiring such minimum capital and surplus.		Was dictated	hington require	
11.4	If yes, show the amount required.		-	689,225	
11.5	Is this amount included as part of a contingency reserve in stockholder's equity?		Yes [ ]	No [ X	]

11.6 If the amount is calculated, show the calculation See RBC calculation or state regulation.

12. List service areas in which reporting entity is licensed to operate:

#### Name of Service Area AL - Autauga, Baldwin, Bibb, Cherokee, Clarke, Colbert, Cullman, Elmore, Escambia, Etowah, Fayette, Jackson, Jefferson, Lauderdale, Lawrence Limestone, Madison, Marshall, Mobile, Monroe, Montgomery, Morgan, Pike, Shelby, Tuscaloosa, Walker, Washington AZ - Coconino, Mohave, Yavapai AR - Baxter, Benton, Boone, Carroll, Clark, Cleburne, Conway, Craighead, Crawford, Crittenden, Faulkner, Franklin, Fulton, Garland, Grant Greene, Hempstead, Hot Spring, Howard, Independence, Izard, Jefferson, Johnson, Lawrence, Little River, Lonoke, Madison, Marion, Miller, Nevada Perry, Pike, Poinsett, Polk, Pope, Prairie, Pulaski, Randolph, Saline, Searcy, Sebastian, Sevier, Sharp, Union, Van Buren, Washington, White CA — Alameda, Butte, Calaveras, Contra Costa, Fresno, Kern, Kings, Lake, Los Angeles, Madera, Marin, Mendocino, Merced, Monterey, Orange, Placer, Riverside, Sacramento, San Bernardino, San Diego, San Francisco, San Joaquin, San Luis Obispo, San Mateo, Santa Barbara, Santa Clara, Santa Cruz, Shasta, Solano, Sonoma, Stanislaus, Tehama, Tulare, Tuolumne, Ventura, Yolo ID - Ada, Bonner, Canyon, Kootenai, Payette IN - Adams, Allen, Boone, Clark, De Kalb, Delaware, Elkhart, Floyd, Gibson, Grant, Hamilton, Hancock, Hendricks, Howard, Huntington, Johnson, Kosciusko, La Grange, La Porte, Lake, Madison, Marion, Marshall, Monroe, Montgomery, Morgan, Noble, Posey, St. Joseph, Tippecanoe, Vanderburgh, Wabash, Warrick, Wells, Whitley ...... KY - Statewide ME - Statewide MO - Barry, Cedar, Christian, Dade, Dallas, Douglas, Greene, Jasper, Laclede, Lawrence, McDonald, Newton, Polk, Pulaski, Stone, Taney, Webster, Wright NE - Cass, Dakota, Dodge, Douglas, Lancaster, Sarpy, Saunders, Washington NH - Belknap, Carroll, Hillsborough, Merrimack, Rockingham, Strafford, OK - Le Flore, Sequoyah SC - Allendale, Anderson, Berkeley, Charleston, Cherokee, Colleton, Dorchester, Greenville, Pickens, Richland, Spartanburg, York TX - Statewide VA - Botetourt, Chesapeake City, Franklin, Norfolk City, Portsmouth City, Roanoke, Roanoke City, Salem City, Virginia Beach City, Albemarle, Alexandria City, Arlington, Charlottesville City, Chesterfield, Colonial Heights City, Craig, Dinwiddie, Falls Church City, Fauquier, Floyd, Goochland, Hampton City, Hanover, Henrico, Hopewell City, Isle of Wight, James City, Loudoun, Louisa, Manassas City, Manassas Park City, Montgomery, Newport News City, Petersburg City, Poquoson City, Powhatan, Prince William, Pulaski, Radford City, Richmond City, Suffolk City, Williamsburg City, Wythe, York, Accomack, Alleghany, Amelia, Amherst, Appomattox, Augusta, Bath, Bedford, Bedford City, Bland, Brunswick, Buckingham, Buena Vista City, Campbell, Caroline, Carroll, Charles City, Charlotte, Clarke, Covington City, Culpeper, Cumberland, Danville City, Emporia City, Essex, Fairfax, Fairfax City, Frederick, Fredericksburg City, Galax City, Giles, Gloucester, Greene, Greenville, Halifax Harrisonburg City, Henry, King and Queen, King George, King William, Lancaster, Lexington City, Lunenburg, Lynchburg City, Madison, Martinsville City, Mathews, Mecklenburg, Middlesex, Nelson, New Kent, Northampton, Northumberland, Nottoway, Orange, Page, Patrick, Pittsylvania, Prince Edward, Prince George, Rappahannock, Richmond Rockbridge, Rockingham, Shenandoah, Southampton, Spotsylvania, Stafford, Staunton City, Surry, Sussex, Warren, Waynesboro City, Westmoreland, Winchester City, Highland, Franklin City, Fluvanna WA - Statewide

Name of Service Area WV - Boone, Cabell, Kanawha, Lincoln, McDowell, Mercer, Monroe, Putnam, Barbour, Berkeley, Braxton, Brooke, Calhoun, Clay, Doddridge, Fayette, Gilmer, Grant, Greenbrier, Hampshire, Hancock, Hardy, Harrison, Jackson, Jefferson, Lewis, Logan, Marion, Marshall, Mason, Mineral, Mingo, Monongalia, Morgan, Nicholas, Ohio, Pendleton, Pleasants, Pocahontas, Preston, Raleigh, Randolph, Ritchie, Roane, Summers, Taylor, Tucker, Tyler, Upshur, Wayne, Webster, Wetzel, Wirt, Wood, Wyoming .....

14.2 If the answer to 14.1 is yes, please provide the following:

1	2	3	4	Assets	Assets Supporting Reserve Credit	
	NAIC			5	6	7
	Company	Domiciliary	Reserve	Letters of	Trust	
Company Name	Code	Jurisdiction	Credit	Credit	Agreements	Other

 Provide the following for individual ordinary life insurance\* policies (U.S. business only) for the current year (prior to reinsurance assumed or ceded):

15.1 Direct Premium Written	\$ 0
15.2 Total Incurred Claims	\$ 0
15.3 Number of Covered Lives	 0

Yes [ X ] No [ ]

*Ordinary Life Insurance Includes
Term(whether full underwriting, limited underwriting, jet issue, "short form app")
Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app")
Variable Life (with or without secondary gurarantee)
Universal Life (with or without secondary gurarantee)
Variable Universal Life (with or without secondary gurarantee)

16. Is the reporting entity licensed or chartered, registered, qualified, eligible or writing business in at least two states?.....

 16.1
 If no, does the reporting entity assume reinsurance business that covers risks residing in at least one state other than the state of domicile of the reporting entity?
 Yes [ ] No [ ]

		1 2020	2 2019	3 2018	4 2017	5 2016
	Balance Sheet (Pages 2 and 3)					
1.	Total admitted assets (Page 2, Line 28)	1,596,487,759	1,246,852,729			
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement					
4.	Total capital and surplus (Page 3, Line 33)					
	Income Statement (Page 4)				, ,	, ,
5.	Total revenues (Line 8)	5.513.801.635	4.345.827.532	3.417.678.000		812.894.10
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
0. 10.	Net investment gain (loss) (Line 27)					
10.	Total other income (Lines 28 plus 29)					
11. 12.	Net income or (loss) (Line 32)					
12.						
40	Cash Flow (Page 6) Net cash from operations (Line 11)	040 554 100	000 000 057	207 505 571	(0.700.557)	(770.07
13.					(2,790,557)	
	Risk-Based Capital Analysis	070 045 000	740 700 400	511 404 700	007 507 440	474 000 7
14.	Total adjusted capital					
15.	Authorized control level risk-based capital	137,325,207	108,214,412			
	Enrollment (Exhibit 1)					
16.	Total members at end of period (Column 5, Line 7)					
17.	Total members months (Column 6, Line 7)	5, 179,311	4,461,256			
	<b>Operating Percentage</b> (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0					
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)					
19.	Total hospital and medical plus other non-health	93.0	04 5	04.1		0E
	(Lines 18 plus Line 19)					
20.	Cost containment expenses					
21.	Other claims adjustment expenses					
22.	Total underwriting deductions (Line 23)					
23.	Total underwriting gain (loss) (Line 24) Unpaid Claims Analysis	3.0		2.2	3.1	
24.	(U&I Exhibit, Part 2B) Total claims incurred for prior years					
	(Line 13, Col. 5)			41,616,444		6,629,8
25.	Estimated liability of unpaid claims-[prior year (Line 13, Col. 6)]					6,971,2
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)	0	0	0	0	
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)	0	0	0	0	
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)	0	0	0	0	
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	
30.	Affiliated mortgage loans on real estate	0	0		0	
31.	All other affiliated					
32.	Total of above Lines 26 to 31					
33.	Total investment in parent included in Lines 26 to					
	31 above.	0	0	0	0	

### SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS Allocated by States and Territories


		Allocated by States and Territories           1         Direct Business Only								
			2	3	4	5 Federal Employees Health	6 Life & Annuity	7	8	9
	States, etc.	Active Status (a)	Accident & Health Premiums	Medicare Title XVIII	Medicaid Title XIX	Benefits Plan Premiums	Premiums & Other Considerations	Property/ Casualty Premiums	Total Columns 2 Through 7	Deposit-Typ Contracts
1.	Alabama AL	(u)	0		0	0	0	0		Contracto
2.	Alaska AK	N	0	0	0	0	Ū	0	0	
3.	Arizona AZ	L	0	0	0	0	0	0	0	(
4.	Arkansas AR	<b>ب</b>	0	464.206.905	0	0	0	0	464.206.905	
5.	California CA	⊢ I	0	1,186,099,608	0	0	0	0	1, 186, 099, 608	
6.	Colorado CO	⊢ N	0		0	0 0	0	0	0	
7.	Connecticut CT	NN.	0	0	0		0	0	0	
8.	Delaware DE	N N	0		0		0		0	
	District of Columbia DC	NN	0	0	0	0	0	0	0	
		N N	0	0	0	0	0	0	0	
	• =	N	0	0	0		0	0	0	
11.	Georgia GA	N	0	0	0	0	0		0	
	Hawaii HI	N	0	05 550 540	0		0	0		
13.	Idaho ID	L	0	25,556,540	0	0	0	0	25,556,540	
	Illinois IL	N	0	0	0	0	0	0		
	Indiana IN	L	0	879,711,859	0	0	0	0	879,711,859	!
	Iowa IA	N	0	0	0	0	0	0	0	!
	Kansas KS	N	0	0	0	0	0	0	0	!
	Kentucky KY	L	0	335,743,768	0	0	0	0	335,743,768	
	Louisiana LA	N	0	0	0	0	0	0	0	
	Maine ME	L	0	85,766,153	0	0	0	0	85,766,153	
	Maryland MD	N	0	0	0	0	0	0	0	
22.	Massachusetts MA	N	0	0	0	0	0	0	0	
23.	Michigan MI	N	0	0	0	0	0	0	0	
24.	Minnesota MN	N	0	0	0	0	0	0	0	
25.	Mississippi MS	N	0	0	0	0	0	0	0	
26.	Missouri MO	L	0	0	0	0	0	0	0	
27.	Montana MT	N	0	0	0	0	0	0	0	
28.	Nebraska NE	L	0	(78,380)	0	0	0	0	(78,380)	
29.	Nevada NV	N	0	0	0	0	0	0	0	
30.	New Hampshire NH	L	0		0	0	0	0	.35,880,415	
	New Jersey NJ	N	0	0	0	0	0	0	0	
	New Mexico NM	N	0	0	0	0	0	0	0	
	New York NY	N	0	0	0	0	0	0	0	
	North Carolina NC	N	0	0	0		0	0	0	
	North Dakota ND	N	0	0	0		0	0	0	
	Ohio OH	N	0	0	0	0	0 0	0	0	
	Oklahoma OK	N	0	0	0		0	0	0	
	Oregon OR	⊢ N	0	0	0	0 0	0	0	0	
	Pennsylvania PA	N	0		0	0	0	0	0	
	Rhode Island RI	NN.	0	0	0	0	0	0	0	
40. 41.		N	0		0	0	0		010 550 676	
		L	0	919,000,070	0		0	0	919,550,676	
	South Dakota SD	NNNNN	0	0	0	0	0	0		
	Tennessee TN	N	0	0	0		0	0	0	
	Texas TX	L	0	0	0	0	0	0		
	Utah UT	N	0	0	0	0	0	0	0	
	Vermont VT	N	0		0	0	0	0		
	Virginia VA	Ļ	0	423,800,286	0	0	0	0	423,800,286	
48.	Washington WA	Ļ	0	574,987,590	0	0	0	0	574,987,590	
	West Virginia WV	L	0	39,602,111	0	0	0	0	39,602,111	
	Wisconsin WI	N	0	0	0	0	0	0	0	
	Wyoming WY	N	0	0	0	0	0	0	0	
	American Samoa AS	N	0	0	0	0	0	0	0	
53.	Guam GU	N	0	0	0	0	0	0	0	
	Puerto Rico PR	N	0	0	0	0	0	0	0	
55.	U.S. Virgin Islands VI	N	0	0	0	0	0	0	0	
56.	Northern Mariana									
	Islands MP	N	0	0	0	0	0	0	0	
	Canada CAN	N	0	0	0	0	0	0	0	
58.	Aggregate other			_	_		_			
	alien OT	XXX	0	0	0	0	0	0	0	
59.	Subtotal	XXX	0	5,513,801,635	0	0	0	0	5,513,801,635	
60.	Reporting entity									
	contributions for Employee	1004	_		0	~	_	^	_	
64	Benefit Plans	XXX	0		0	0	0	0	U	
61.	Total (Direct Business)	XXX	0	5,513,801,635	0	0	0	0	5,513,801,635	
	DETAILS OF WRITE-INS									
8001.		XXX	0	0	0	0	0	0	0	
002.		XXX								
8003.		XXX								
3998.	Summary of remaining									
	write-ins for Line 58 from		-	_	-	-	_	-	_	
		1000	0	0	0	0	0	0	0	
2005	overflow page	XXX	0							
3999.	overflow page Totals (Lines 58001 through 58003 plus 58998)(Line 58		0							

L - Licensed or Chartered - Licensed insurance carrier or domiciled RRG...... E - Eligible - Reporting entities eligible or approved to write surplus lines in the state....... N - None of the above - Not allowed to write business in the state......


(b) Explanation of basis of allocation by states, premiums by state, etc. The Company reports premium based on the situs of the contract


R - Registered - Non-domiciled RRGs......0 Q - Qualified - Qualified or accredited reinsurer......0

......40



Tony ducted on the ship minimum and reference of the second and reference





40.2

# ANNUAL STATEMENT FOR THE YEAR 2020 OF THE Arcadian Health Plan Inc. **OVERFLOW PAGE FOR WRITE-INS**

Additional Write-ins for Exhibit of Nonadmitted Assets Line 25									
		1	2	3					
				Change in Total					
		Current Year Total	Prior Year Total	Nonadmitted Assets					
		Nonadmitted Assets	Nonadmitted Assets	(Col. 2 - Col. 1)					
2504.	Deposits	0							
2597.	Summary of remaining write-ins for Line 25 from overflow page	0	71,616	71,616					